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ABSTRACT 
Characterizing TG2 autoantibody response in Celiac Disease 
PhD Student: Szilvia Bakó1 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Year: 2012-2015
Tutor: Prof. Daniele Sblattero1                                                                   Coordinator: Prof. Claudio Santoro1 
 
1 Department of Health Science and Interdisciplinary Research Center on Autoimmune Diseases, University 
of Eastern Piedmont, Novara, Italy
Background: Celiac Disease (CD) is  a  gluten sensitive enteropathy with autoimmune features, 
characterized  by  the  destruction  of  intestinal  epithelium  and  the  production  of  IgA and  IgG 
antibodies against gluten and self antigen tissue transglutaminase (TG2). Because of the fact that 
TG2 acts not only as key player in the disease but also as a self antigen studying the autoimmune 
response  against  this  enzyme  is  crucial  for  understanding  CD.  Numerous  studies  aimed  to 
investigate the antibody response due to the possible role anti TG2 antibodies play in the onset of 
the  disease,  however  there  are  still  many  questions  to  be  answered.  Phage  display  antibody 
technology have been proved to be an efficient  tool  in  the study of  autoimmune diseases,  and 
because of this we selected this method for dissecting the autoimmune response in CD.
Results: We were able to generate and classify antibodies in phage expressed scFv format first due 
to  their  specificity  and  second  by  competing  them with  reference  antibodies.  Antibodies  were 
clustered into four Epitope groups, with great majority belonging to Epitope 1., the VH5 cluster. 
Antibodies representing each epitope cluster were analyzed in scFv-Fc format. It was shown that 
Epitope 1. antibodies recognize a region in TG2 molecule overlapping with fibronectin binding site 
while other epitope groups recognized a different region. Three out of four epitope clusters were 
able to stain cell surface TG2 (csTG2). Of the four epitope groups only Epitope 2. had inhibitory 
effect on TG2 enzymatic activity in vitro.                                                                                                                                               
By reconstructing a VH5 antibody from IgG1 format into scFv format we generated two constructs 
with different VH/VL orders that retained specificity. The VH chain was substituted with Vk chains 
originating from three cDNA libraries generated from CD patients. The Vk usage was restricted 
IGKV1-5*03 F, IGKV1-39*01 F, IGKV1-12*01 F chains, IGKV1-39*01 being most abundant 
chain. Two construct with original VH/VL and four selected clones with Vk chains coming from 
cDNA libraries were characterized in scFv-Fc format. All clones were shown to recognize the 
region on TG2 overlapping with fibronectin binding site. Most but not all of scFv-Fcs recognized 
csTG2. None of the antibodies showed inhibitory effect on TG2 enzymatic activity corresponding 
to what we saw in the case of VH5 antibodies . 
Conclusion: In this work we demonstrated that phage antibody display is an extraordinary tool to 
study the autoantibody response in CD. The generated antibodies in phage expressed scFv format 
were able to mimic the natural antibody response, and a straightforward reconstruction in scFv-Fc 
format allowed the precise analysis of the disease. The study not only provided an insight into the 
pathology of CD but also revealed the possibilities of a novel technology to analyze autoimmune 
diseases.
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Introduction
INTRODUCTION 
Chapter 1. Tissue transglutaminase 
1. 1. Transglutaminases 
Transglutaminases (TGases) are widely distributed group of enzymes catalyzing the post- 
translational modification of proteins through acyl transfer reactions involving γ-carboxamide group 
of peptide-bound glutamine and the ε-amino group of peptide-bound lysine, resulting in a ε-(γ- 
glutamyl) lysine isopeptide bond [1]. The cross linked products often of high molecular mass are 
highly resistant to proteolysis and their accumulation can be found in various tissues and processes 
where they play an important role. The term transglutaminase was first introduced by Clarke et al in 
1957 [2] where they were describing the transamidating activity observed in guinea pig liver. Since 
these findings enzymes having TGase activity have been identified in micro organisms [3], plants 
[4], amphibians [5], fish [6], and birds [7]. In mammals nine TGase isoenzyme have been identified 
at the genomic level, however only eight have been characterized at protein level. All mammalian 
forms of TGases having structural homology are members of the papain -like superfamily of 
cysteine proteases [8], and the tissue content of them is tightly regulated at transcriptional level 
(Table1.1). Transglutaminase 2 (TG2) is the most abundant and studied member of the TGase 
enzyme family including TG1, TG3 and TG5 isoforms expressed in epithelial tissue, TG4 expressed 
in prostate gland, factor XIII expressed in blood, TG6 and TG7 most prominently distributed in the 
testis and lungs [9]. A further member of TGase family is band 4.2 an enzymatically inactive protein 
component of erythrocyte membrane [10]. The characteristics of each member of the family 
include: 
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• Keratinocyte transglutaminase (TG1): localized in squamous epithelia, keratinocytes and 
cytosolic membrane, activated by proteolysis, has a barrier function in stratified squamous 
epithelia and plays a central role in keratinocyte differentiation.   
• Tissue transglutaminase (TG2): exists in extracellular and intracellular form, ubiquitously 
distributed in various tissue types. Plays role in many biological processes including apoptosis, 
cell survival, signaling, cell differentiation, matrix stabilization, endocytosis and so forth. 
• Epidermal transglutaminase (TG3): cytosolic protein, requires proteolysis to become active 
and get involved in the terminal differentiation of keratinocytes, hair follicles. 
• Prostate transglutaminase (TG4): expressed in prostate gland, prostatic fluids, extracellular. 
Plays key role in the fertility of rodents where it is involved in semen coagulation. 
• TG5: Ubiquitously expressed cytosolic protein, predominant in female reproductive tissues and 
skeletal muscle, playing role in epidermal differentiation.
• TG6: Showing high homology with TG2, distributed in testis, lungs, brain involved in the 
development of central nervous system and late stage cell envelope formation in the epidermis 
and hair follicle.
• TG7: Ubiquitously expressed , prominent in testis and lungs.
• Factor XIII: Converted  into the active TGase Factor XIIIa (plasma TGase) by a thrombin-
dependent proteolysis, distributed in chondrocytes, platelets, astrocytes, macrophages and 
dendritic cells in the dermis. Involved in wound healing, blood clotting and bone growth. 
• erythrocyte protein band 4.2 (Band 4.2): distributed in the surface of erythrocyte 
membranes, bone marrow, fetal liver and spleen. Key component of erythrocyte skeletal 
network, maintaining erythrocyte shape and mechanical properties. 
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Table 1.1. Transglutaminases characterized at protein level [11] 
1. 2. Tissue transglutaminase a multifunctional enzyme
Tissue transglutaminase (TG2) is the most ubiquitous and diverse member of the transglutaminase 
family with a great variety of biological functions. The human transglutaminase gene localized to 
the chromosome 20q11-12 is composed of 13 exons and spams 37kb.[12] The monomeric TG2 
protein is composed of 687 amino acids, (MW ~ 78kDa) including four distinct domains. N 
terminal β-sandwich with the fibronectin and integral binding site, catalytic core containing the 
catalytic tridad Cys277-His335-Asp358 for the acyl- transfer reaction, a conserved Trp essential 
for catalytic activity [13] a Ca2+
 
binding region and two C terminal β-barrels, with β-barrel 1 
containing the GTP binding site, while β-barrel 2 containing a phospholipase C binding sequence 
[14] (Figure 1.1.) 
Figure 1.1. Structural and functional domains of TG2 [15]
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Figure 1.2. TG2 conformations. The N-terminal β-sandwich is shown in blue (N), the catalytic domain 
(Core) in green, and the C-terminal β-barrels (β1 and β2) in yellow and red, respectively. (A) GDP-bound 
TG2 [16]. (B) TG2 inhibited with the active-site inhibitor [17]. (C) The N-terminal β-sandwich and catalytic 
domains of the two structures are superimposed, highlighting the conformational change. The GDP-bound 
structure is shown in blue and the inhibitor-bound structure in gold.
In spite of the fact that TG2 was found with high expression in various tissues such as in endothelial 
cells, red blood cells and smooth muscle cells, it is still considered as a stress related protein, with 
its expression up regulated by physiological and pathological stimuli. Retionic acid (RA) is a well 
known inducer of TG2 expression both at mRNA and protein level [18]. A number of inflammatory 
cytokines and growth factors can induce TG2 expression such as transforming growth factor β1 
(TGFβ1) [19], interleukins [20] and tumor necrosis factor α (TNFα) [21], thought to up regulate 
TG2 by activating nuclear factor κB (NF-κB). The activity of TG2 is tightly controlled within the 
intracellular environment, due to the presence of low Ca2+ and the inhibitory effects of GTP and 
GDP on its cross-linking ability [22]. In normal physiological conditions TG2 exists in a closed 
conformation where the active site of TG2 is hidden in a cleft preventing substrate binding and the 
C-terminal β-barrel domains tightly fold back for the catalytic core domain [23] (Figure 1.2.). 
Under stress, disturbance of the intracellular Ca2+ balance may cause transient loss of Ca2+ 
homeostasis activate TG2 into its catalytically active, open conformation. Ca2+ binding activates 
TG2 by inducing a conformational change increasing the inter domain distance between the 
catalytic core and the two C-terminal β-barrel domains up to 15nm. This results in the relaxation, 
widening of the whole molecule making the active site accessible for TG2 substrates [16, 17, 24]. In 
contrast, GTP binding likely stabilizes the closed conformation. Although GTP is considered to be a 
negative regulator of TGase activity, it has been indicated that the GTP binding is required to 
display transamidation activity of TG2 [25].
 12
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1. 3. Enzymatic functions of TG2
1. 3. 1. Transamidating activity
Two main biological functions of TG2 are transamidation and GTP-binding, with Ca2+
 
levels acting 
as a switch between them. When the transamidating activity is turned on the catalysis of post-
translational modifications of proteins is hallmark of TG2 activity [26]. The two step process 
involves as a first step the formation of a thioester bond with the enzyme’s active cysteine site via 
the transamination of γ-carboxamide group of a specific protein-bound glutamine substrate, 
accompanied by the release of ammonia. The second step includes the transfer of acyl intermediate 
to a nucleophilic substrate either the ε-amino group of a distinct protein-bound lysine residue [27] 
or primary amines such as polyamines and histamine. These bonds are resistant to chemical and 
physical degradation and are essential for stabilizing the ECM [28, 29]. Isopeptide bonds formed by 
TG2 also play a key role in apoptosis where they prevent inflammation by ensuring that 
intracellular contents of dying cells are not released to the extracellular environment [30]. Water can 
also act as a nucleophile causing deamidation where the acyl-donor glutamine residue is converted 
to a glutamate residue [31] (Figure 1.3.). 
 
Figure 1.3. Enzymatically active TG2 catalyzes Ca2+-dependent acyl-transfer reaction between γ-
carboxamide group of a protein-bound glutamine and either the ε-amino group of a distinct protein-bound 
lysine residue (covalent protein cross-linking) or primary amines such as polyamines and histamine. Water 
can replace amine donor substrates, leading to deamidation of the recognized glutamines. [32].
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1. 3. 2. GTPase activity of TG2 
Under normal conditions in the intracellular environment the transamidating activity of TG2 is 
turned off due to the low level of calcium and the high level of GTP, inhibiting this function of the 
enzyme. TG2 is involved in transmembrane signaling by its GTPase activity combined with its 
ability to interact and signal through receptors [33-35]. TG2 was shown to interact with several 
receptors, facilitating hormone-receptor mediated transmembrane signaling pathways, involving the 
classical G-protein-coupled receptors.TG2 has been shown to directly interact with PLC δ1, a key 
player in the signal transduction process for many receptors [36]. A region of 12 amino acids 
between Leu661 and Lys672 in TG2 was identified as the PLC interaction site while the TG2 
interaction site in PLC δ1 was shown to be located within the C2 domain of the enzyme [14, 37]. 
PLC δ1 not only serves as a guanine nucleotide exchange factor (GEF) but also as GTP hydrolysis 
inhibiting factor (GHIF) for TG2. These functions of PLC δ1 for TG2 facilitate TG2-mediated 
signaling. Other receptors, which interact with TG2 and mediate transmembrane signaling, are the 
thromboxane receptor [38] and the oxytocin receptor [39]. Both of the interactions are regulated by 
activation of PLC.  
1. 3. 3. Pro and Anti-apoptotic effect of TG2 
TG2 was reported to be involved in apoptosis [40] and it has been proposed that the cell type, the 
kind of stressor, intracellular localization, and transamidation activity of TG2 determine whether it 
promotes pro-apoptotic or anti- apoptotic responses [41]. The pro-apoptotic effect of TG2 is due to 
its cross linking activity, which requires millimolar concentration of calcium. Stressful conditions 
can generate reactive oxygen species (ROS) and also trigger the release of Ca2+ from the 
endoplasmic reticulum (ER), resulting in the activation of TG2 and cross linking of intracellular 
proteins initiating the apoptotic process [42, 43]. TG2 initiates apoptosis by mediating the crosstalk 
between dying and phagocytic cells and also ensures that once apoptosis initiated it is completed 
without inflammation or tissue injury [44]. TG2 can indirectly promote apoptosis by prompting the 
activation of TGF -ß release by macrophages, which can lead to the death of various cells [45, 46] . 
Additionally, TG2 can promote chemoattractant formation and the release of phosphatidylserin, to 
aid macrophage migration to the site of apoptosis and eventually the recognition of apoptotic cell 
[47]. 
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TG2 may also have anti-apoptotic effect, which is independent from its transamidation and cross-
linking activities. Nuclear TG2 protects cells by interacting with retinoblastoma protein pRb, 
polymerizing the alpha-inhibitory subunit of the transcription factor NF-kappaß, regulating the 
transcription of several anti-apoptotic genes [48]. Similarly TG2 can translocate to the plasma 
membrane where it serves as a co-receptor for integrin, promoting its interaction with fibronectin. A 
plausible scenario is that pro-apoptotic and anti-apoptotic effects of TG2 are dependent on the 
activation pathways and localization of the protein, with nuclear and extracellular TG2 as anti-
apoptotic and cytosolic TG2 is pro-apoptotic [49]. 
1. 3. 4. PDI activity of TG2 
TG2 was proposed to have protein disulphide isomerase (PDI) activity. PDI is a typical resident 
protein of the lumen of the endoplasmic reticulum (ER) on the surface of eukaryotic cells, 
catalyzing the formation, breakup, and exchange of disulphide bonds via cysteine residues in 
various proteins [50-52]. The PDI activity of TG2 was found to be independent from Ca2+ and GTP 
[53] but required free sulfhydryl groups of the protein for catalysis. Oxidants/antioxidants influence 
PDI activity, which is strongly amplified by oxidized glutathione but inhibited by its reduced form. 
These indicate that TG2 might be able to function as PDI in cytosol, where the majority of the 
enzyme is found in cells and where the concentrations of Ca2+ are very low and of nucleotides fairly 
high. The distribution of PDI is generally believed to be specific in the lumen of the ER, but there 
have been recent reports of its distribution in non-ER fractions including cytosol, nucleus and cell-
surface fractions [54]. PDI function of TG2 was also supported by analysis of TG2-/- mice which 
had abnormalities in the mitochondrial respiratory chain and ATP production [55]. The underlying 
molecular mechanism may depend on defective disulphide bond formation in the ATP synthase 
complex and other components of the respiratory chain [56], including ADP/ATP transporter 
adenine nucleotide translocator (ANTI) which was incorrectly assembled and dysfunctional in the 
absence of PDI activity of mitochondrial TG2 [57]. 
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1. 3. 5. Protein kinase activity of TG2 
Evidence shows that cytosolic TG2 under specific physiological conditions can be translocated into 
the nucleus where it either crosslinks proteins or interact with them non-covalently [58]. The 
increase in Ca2+ concentration can result in the translocation of TG2 into the nucleus and 
subsequent increase in its transamidation activity [59]. Sequence analysis of TG2 showed the 
presence of a putative bipartite nuclear localization sequence (NLS) which indicates the active 
transport of TG2 to the nucleus [60]. The p53 oncoprotein was implied to be a substrate for the 
protein kinase activity of TG2 in the nucleus. TG2 induced phosphorylation was shown to interfere 
with Mdm2 binding suggesting that this mechanism can facilitate apoptosis [61]. Additional 
substrates of nuclear TG2 protein kinase activity include histones H1 and H3, indicating that TG2 
night be involved in modulating the conformation of nucleosomes [62]. It is proposed that the 
interaction is involved in the condensation of chromatin in apoptotic nuclei [63]. TG2 was also 
reported to catalyze the cross-linking of polyamine binding proteins [64] and polyamines, involved 
in the modulation of chromatin structure and function [65]. Because putrescine, a polyamine, is 
incorporated by histones via a transglutaminase reaction, TG2 could contribute to polyamine-
mediated chromatin condensation by direct interaction and covalent modification of histones.  
1. 4. Functions of extracellular TG2 
TG2 is predominantly localized within cells in the cytosol but can also be found in other cell 
compartments such as plasma membrane and the nucleus. TG2 is externalized from various cell 
types including fibroblasts, osteoblasts, endothelial cells, smooth muscle cells and monocytes/
macrophages [66, 67]. However it is not fully understood how TG2 is secreted as there are no 
secretory signal sequences and hydrophobic or transmembrane domains in the protein. Available 
data suggests that TG2 is externalized by an unconventional mechanism. A plausible scenario is that 
the unconventional secretion pathway of TG2 involves phospholipid dependent delivery into 
recycling endosomes [68] (Figure 1.4).  
 16
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Figure 1.4 Unconventional secretion pathway of TG2 involving phospholipid-dependent delivery into 
recycling endosomes. [29] 
The process occurs most likely in two steps where TG2 initially tethers to the endosomal 
phosphoinositides followed by binding the endosomal membrane through unidentified membrane 
proteins. Once secreted outside the cell TG2 promotes cell adhesion, migration and stabilization of 
the ECM by cross-linking several ECM proteins. A number of proteins are potential substates of 
TG2 cross-linking including fibronectin (FN), vitronectin, osteonectin, osteopontin, laminin, 
fibrillin, collagen I, collagen II, collagen V, collagen VI and XI. [69-71]. Collagen I can also be 
cross-linked by TG2 leading to high resistance to protease degradation and matrix turnover.  TG2 
cross-liked collagen shows low toxicity to cells providing an ideal biomaterial in wound healing, 
enhancing cell adhesion, proliferation and differentiation compared to native collagen [72] ECM 
and cell–matrix interactions are regulated by cross-linking of ECM proteins and also by proteolysis 
of them, where matrix metalloproteinases (MMPs) are playing a key role [73]. These proteinases, 
such as MT1-MMP, participate not only in ECM degradation, but also degradation of TG2 on tumor 
cell surfaces [74]. MT1-MMP is also activator of MMP2 [75, 76] which interact with the core 
domain of TG2 and direct its cleavage leading to the elimination of the catalytic and adhesion 
activity [77]. The degradation of TG2 by MMP2 plays a significant role in adhesion/migration 
related physiopathological conditions. 
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1. 5. Interacting partners of TG2 
TG2 is a multifunctional enzyme with several substrates and interacting partners.Until now, 159 
TG2 substrates, and 46 interaction partners, have been identified, according to TRANSDAB online 
database (http://genomics.dote.hu/wiki/). The two-third of the intracellular TG2 substrates in 
TRANSDAB are reported to be primarily in the cytoplasm, supporting the fact that TG2 is 
predominantly a cytoplasmic protein. STRING, the database of known and predicted protein 
interactions (http://string-db.org/), predicts over 100 possible protein interaction for TG2 with 50% 
confidence. Identified interacting partners of TG2 include proteins involved in interaction with 
ECM such as fibronectin and cell signaling as integrin α subunit and PLC-δ1 (Figure 1.5) 
Figure 1.5. TG2 interacting protein network generated by STRING. 
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1. 5. 1. Fibronectin and TG2 interaction in the ECM 
Fibronectin (FN) is a high molecular weight glycoprotein present in plasma and extracellular matrix 
(ECM) produced by hepatocytes and many other cell types [78, 79]. FN is a dimer of 230-250 kDa 
subunits joined by disulfide bonds in physiological conditions, consists of highly structural domains 
separated by flexible polypeptide segments. Each subunit is composed of three type of modules of 
which there are 12 type 1 (F1), two type 2 (F2) and 15-17 type 3 (F3) modules per subunits 
depending on splice variation (Figure 1.6) [78, 80]. These modules compose various functional 
domains, from the N-terminal there are heparin and fibrin-binding domain (30 kDa), collagen-
binding domain (40 kDa), fibrin-binding domain (20 kDa), cell-binding domain (57 kDa), heparin-
binding site (35 kDa) and fibrin-binding site (30 kDa). The domains are relatively resistant to 
proteases and contain the binding sites for macromolecules such as collagen, fibrinogen, fibrin, and 
proteoglycans, as well as cells [81].  
Figure 1.6. Structural domains of fibronectin molecule. The 42kDA domain responsible for TG2 binding 
is indicated in red. (modified from [82] ) 
FN has been reported to be a substrate for TG2 enzymatic activity and high molecular weight 
covalently cross-linked FN complexes may be formed by TG2 [83, 84]. However the formation of 
matrix fibrils does not require the enzyme’s cross-linking function but depends on the binding to 
FN. TG2 binds FN with high affinity (Kd ~8nM) and 2:1 stoichiometry [85]. The binding involves 
the 42 kDa gelatin binding domain of FN consisting of modules I6II1,2,I7-9 [84, 86].  
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The N-terminal of TG2 is involved in the interaction with FN and the functional sequences required 
for the binding are located within the amino acids 89-140 of the protein [87]. The major functional 
sequence has been demonstrated that the β5/β6 hairpin of the first domain represents the major 
recognition site on TG2 molecule for the interaction with FN. This hairpin forms a prominent 
“finger” which is extended well beyond the globular first domain with its tip located aside from any 
other parts of TG2 molecule [16] making the β5/β6 hairpin well positioned for interaction with the 
large FN molecule. Surface TG2 on isolated hepatocytes and endothelial cells was shown to bind 
FN and mediate it’s cross-linking into high molecular weight complexes [88]. Reduced expression 
of TG2 in endothelial cells led to an inhibition of the cross-linking of Fn [89] and, conversely, up-
regulation of TG2 in Swiss 3T3 fibroblasts increased the amount of the cross-linked FN.  
1. 5. 2. Other extracellular interacting partners of TG2 
TG2 is involved in cell adhesion and migration by interacting with integrins mediating their 
association with FN which potentiates signaling. TG2 interacts with integrins through non covalent 
interaction involving the β1, β3 and β5 intern subunits of integrins [90, 91]. The exact mapping of 
integrin binding site on TG2 molecule has not been reported yet, however its most likely involves 
the first and fourth domains of TG2 whereas the TG2 binding site in integrins includes several 
membrane-proximal epidermal growth factor (EGF) like repeats of β subunit away from the FN 
binding site. Integrins are relatively low affinity receptors for ECM proteins including FN. In 
contrast TG2 binds high with affinity the 42 kDa fragment of FN, lacking the integrin binding site 
and this way creates additional binding sites between the two molecules.[90]. This potentially 
doubles the number of sites in the FN matrix that cells can access in adhesion and spreading. There 
are different models proposing the role of TG2 in cell adhesion (Figure 1.7). In one scenario TG2 
serves merely as a bridge between integrin and FN. This strengthen adhesion because of the higher 
affinity and by allowing a second integrin molecule to access the FN chain. However there is also 
the possibility for even more stable ternary complexes where each protein interact with two other. 
Either scenario provides an explanation for increased cell adhesion and spreading on FN.  
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Figure  1.7.  Model  proposing  the  role  of  TG2 in  cell  adhesion  and spreading  by  forming  ternary 
complexes with integrin and FN. (A) Integrin-mediated adhesion to FN in the absence of TG2. (B) TG2 
enhancing adhesion acting as a bridge between integrins and FN. (C) TG2 enhancing adhesion by mediating 
the formation of ternary complexes where all three proteins interact with each other. [90]
Increased expression of TG2 has been described in epithelial malignancies, specifically in ovarian, 
breast and pancreatic cancers [92-94]. TG2 has been linked to various functions in cancer but most 
importantly it acts as a promoter of chemotherapy resistance [95, 96] and a facilitator of metastasis 
[94, 97, 98]. It has been demonstrated that TG2 increases peritoneal metastasis [94, 98] and linked 
this process to β integrin mediated ovarian cancer cell adhesion to the peritoneal matrix. TG2 
induces epithelial-to-mesenchymal transition (EMT) [98] which is a critical step in the initiation of 
metastasis and that the FN-binding domain of TG2 is sufficient to initiate this process [99, 100]. In 
addition, the TG2-mediated interaction between β integrin and FN activates cell survival pathways 
[90] and contributes to doxorubicin resistance in breast cancer cells [101], as well as cisplatin and 
dacarbazine resistance in melanoma cells [102]. Because of these findings TG2-FN interaction has 
become a potential target for cancer therapies. TG2 and FN interaction has been analyzed by 
AlphaLISA assay [103] and the application was used to study a ChemDiv library of chemical 
compounds leading to the discovery of potent TG2 inhibitors [104]. TG2-FN interactions 
characterized by a TG2 hairpin inserting a deep pocket of FN generating an attracting target for 
small molecular inhibitors, the most potent a diamino-pyrimidine derivate TG53 [104].  
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Another important binding partner of TG2 is the heparin sulphate proteoglycan, syndecan-4 (Figure 
1.8). Syndecan-4 transmembrane component present together with integrins in focal adhesions 
where it interacts with the Hep-2 region of fibronectin. [105]. The high affinity interaction of TG2 
and syndecan-4 is thought to maintain the activation of protein kinase Cα, important for controlling 
integrin levels and clustering throughout cell surface [106, 107]. Furthermore the fibronectin-TG2 
heterocomplexes interact with syndecan-4 what may serve as a parallel adhesive/signaling platform 
cells may utilize in the case of integrin-deficiency [108, 109]. TG2 also reported to act as a 
scaffolding protein between platelet-derived growth factor receptor (PDGFR) and integrin, 
amplifying signaling from the membrane to the cell’s interior this way stimulating cell adhesion and 
migration [110] (Figure 1.8). 
Figure 1.8 Types of TG2-containing adhesive/signaling complexes present on the cell surface involving 
main interactors of extracellular TG2. [29] 
 22
Introduction
1. 6. Pathological implications of TG2
TG2 has been implicated in a wide variety of pathological states:neurodegenerative disorders 
(Huntington‟s, Alzheimer‟s), fibrosis and scarring, cancer and autoimmune disease such as Celiac 
disease. One of the most well known and studied pathological role of the enzyme is involved in 
Celiac disease, which will be discussed more detailed in the next chapter. 
1. 6. 1. TG2 in neurodegenerative diseases 
TG2 has been implied to be involved in several neurological diseases such as Huntington’s disease 
[111, 112], Alzheimer’s disease [113, 114] and Parkinson’s disease [115]. 
Huntington’s disease 
Huntington's disease (HD) is a dominant, monogenic, neurodegenerative disorder affecting 1 in 
10,000 individuals. The disease is characterized by progressive loss of gross motor skills, 
development of chorea (involuntary movements), subcortical dementia and emotional disturbance. 
The disease is caused by a mutation in the huntingtin gene, an expanded CAG repeat, which 
encodes an abnormally long polyglutamine (polyQ) repeat in the N-terminus of huntingtin protein. 
When the length of the polyQ domain exceeds 35-40 glutamines, the disease occurs. Despite the 
widespread expression of huntingtin, the brains of HD patients show selective neuronal loss in the 
striatum and the deep layers of the cerebral cortex. Aggregation of mutated huntingtin, 
transcriptional dysregulation, altered energy metabolism, impaired axonal transport and altered 
synaptic transmission culminate in neuronal dysfunction and cause death. Huntingtin was found to 
be primarily associated with microtubules as well as other huntingtin-associated proteins [116] 
[117]. TG2 was shown to co-localized with huntingtin and β-tubulin and it was proposed that 
microtubules could serve as binding site, bringing together TG2, huntingtin, and other TG2 
substrates for TG2 dependent cross-linking [118]. Another protein reported to interact with TG2 and 
contribute to HD pathology was a calcium binding protein, calmodulin. Calmodulin was found to 
co-localize with TG2 and mutant huntingtin in the intranuclear inclusions in the HD brain. It has 
been shown that calmodulin is might increase TG2 activity by regulating calcium concentration 
[119].  
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Because mutant huntingtin interacts with both TG2 and calmodulin in HD brain, it was suggested 
that huntingtin might be also involved in increasing TG2 activity and subsequently its own cross-
linking by bringing calmodulin and TG2 in close proximity. Thus, calmodulin indirectly regulates 
TG2-mediated cross-linking of huntingtin and formation of stable aggregates and inclusions in HD 
[120]. 
Alzheimer’s disease  
Alzheimer‟s disease (AD) is the most common age-related neurodegenerative disorder, associated 
with the selective damage of brain regions and neural circuits, including neurons in the neocortex, 
hippocampus, and amygdala. Dysfunction and loss of neurons in these neural circuits results in 
impaired memory, thinking and behavior. Many factors likely involved in the pathogenesis of AD, 
like traumatic brain injury [121], aging [122], inflammation [123], ischemic damage [124] and brain 
stress [125] overly induce TG2 expression and/or activity. AD is characterized by pathological 
lesions such as intraneuronal neurofibrillary tangles (NFTs), extracellular senile plaques and 
cerebral amyloid angiopathy. Major component of neurofibrillary tangles is aggregated 
hyperphosphorylated tau protein [126], whereas senile plaques and cerebral amyloid angiopathy 
largely consist of aggregated amyloid beta (Aβ) peptide [127]. Conformational changes of both Aβ 
[128] and tau [129] may lead to their aggregation. In addition, both of these proteins are particularly 
neurotoxic when in such an aggregated state [130]. It has been hypothesized that TG2 may be 
involved in the pathogenesis of AD by facilitating the formation of one or both of these insoluble 
lesions. Senile plaques contain amyloid fibrils composed of the Aβ, and it has been shown that TG2 
can cross-link Aβ1-28 [131], Aβ1-42 [132] and APP [133]. It has been demonstrated that TG2 
induces monomeric Aβ to rapidly form protease-resistant oligomers and aggregates in a time- and 
concentration-dependent manner similar to self-assembly, and lowers the concentration for Aβ 
oligomerization, so it can occur at physiological Aβ levels [134]. Tau protein is an excellent TG2 
substrate both in vitro and in vivo [135] and Tau protein cross-linking catalyzed by TG2 has been 
confirmed in tau transgenic mice that develop neurofibrillary tangles and have cross-linked tau 
protein [136].
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1. 6. 2. TG2 in fibrosis and scarring
TG2  is  involved  in  many  pathological  conditions  where  it  is  thought  that  the  wound-healing 
response does not process normally. Chronic stress resulting in fibrotic disease is caused by an 
excess of ECM, cross-linked by TG2 [137-139]. In addition to causing increased matrix deposition 
by activating TGFβ1, TG2 cross-linking in the ECM has been shown to result in a reduction of 
matrix turnover leading to net deposition and accumulation [140]. TG2 has also been reported to be 
responsible for the progression and stabilization of atherosclerotic plaques, where it prevents plaque 
rupture with it’s cross-linking activity [141]. Hypertropic scarring, characterized by excessive 
collagen deposition by prolonged activation of myofibroblasts, also involves TG2 [142], in a 
process that can be prevented by applying TG2 inhibitors [143]. The importance of TG2 in renal 
fibrosis has been highlighted by the beneficial effects of membrane soluble irreversible TG2 
inhibitor R283 or membrane-impermeable irreversible TG2 inhibitor R281 [144] caused in this 
condition. Targeting extracellular TG2 with membrane-impermeable inhibitors did not affect the 
transcription of major ECM proteins or MMP-1 nor the activity of TGFβ1 suggesting that the cross 
linking activity of the enzyme on the ECM was responsible for the effect [145]. 
1. 6. 3. TG2 in cancer 
The ability of malignant cells to proliferate and invade surrounding tissues is characterized by 
insensitivity to growth signals and resistance to apoptotic cell death, in which the GTP binding and 
transamidating activity of TG2 have potential role [146]. Over expression of TG2 in malignant 
hamster fibrosarcoma cells led to delayed progression from S-phase to G2/M [34] supporting that 
reduced TG2 activity is associated with tumor growth and metastasis [147]. In spite of the fact that 
intracellular TG2 has suggested to have pro- and anti-apoptotic effect, the increased TG2 expression 
has been correlated with increased apoptotic index in human breast carcinomas [148]. Cytosolic 
TG2 can be anti-apoptotic by activating NF kappa B pathway [92]. In the extracellular environment 
TG2/fibronectin is also associated with cell survival via interaction with integrins [149] and 
syndecan 4 [110]. It has been reported that MT-MMPs regulate cancer cell attachment and motion 
by digesting cell surface TG2. While the digestion of cell surface TG2 suppressed cell adhesion and 
locomotion on fibronectin, the interaction of fibronectin and TG2 protected cell surface TG2 from 
digestion, this way prompting cell adhesion and locomotion [74].  
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The effect of exogenously added TG2 to angiogenesis models demonstrated that there was an 
accumulation of ECM proteins without causing an increase in cell death [150]. It has also been 
implied that increase in matrix rigidity caused by TG2 cross-linking is responsible for alteration in 
cell behavior in mouse model with CT26 colon carcinoma. In a study involving 200 cases of human 
breast cancer, an increased TG2 level in the stroma surrounding the tumor was associated reduction 
in lymph node metastasis [151]. Increase TG2 expression has also been associated with the 
development of drug resistance and metastatic phenotype [152, 153]. Aberrant expression of TG2 in 
breast cancer has been linked to the fact that TGM2 gene is among the selected genes whose 
expression is altered by hypo- and hypermethylation in drug resistant breast cancer cells [154]. TG2 
has been implied to induced epithelial-to-mesenchymal transition which associated with metastatic 
spread and poor disease outcome in patients with breast cancer [155] and malignant pleural 
mesothelioma. 
1. 7. Inhibition of TG2
TG2 is implicated in a range of pathologies, demonstrating a need for potent TG2-specific 
inhibitors. The pathogenic role of TG2 is primarily linked to its cross-linking and deamidation 
activity, while the use of inhibitory molecules in biological systems gave promising results in a 
number of disease models, proposing a potential use for therapeutic treatment of human diseases. 
Upon their mechanism of inhibition, TG2 inhibitors can be divided into two classes: reversible 
inhibitors and irreversible inhibitors. 
1. 7. 1. Reversible TG2 inhibitors 
Reversible TG2 inhibitors prevent TG2 activity by blocking substrate access to the active site 
without covalently modifying the enzyme. In the early studies aiming to inhibit TG2, primary 
amines were used [156, 157], which inhibit the native function of the enzyme by competing 
substrates in the cross-inking reaction. Zn2+ as a bivalent cation was also used as an early reversible 
inhibitor for competing Ca2+ for the binding sites [158, 159]. Cystamines are inhibitors, capable of 
competitive amine inhibition [160].  
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It was also shown that cystamines able to inactivate TG2 in time-dependent manner by forming 
mixed disulphide bonds between TG2 active site cysteine and cystamine [161-163]. Despite their 
lack of selectivity, particularly when applied in biological settings [164], cystamines are still widely 
used inhibitors. Recently used reversible inhibitors may also be competitive to the acyl-donor 
substrate. Cinnamoyl inhibitors such as trans-cinnamoyl derivates [165], cinnamoyl benzotriazolyl 
amides [166], and azachaltones were shown to be potent inhibitors (Figure 1.9). These inhibitors 
were shown to be competitive in respect to the donor substrate, supporting that inhibitors bind to the 
hydrophobic groove of the acyl-donor binding site, this way blocking the substrate access to the 
active site. Acylideneoxoindoles [167] are another scaffold of reversible TG2 inhibitors based on 
the structure of isatin, whose analogs are widely used as reversible inhibitors of Cys-dependent 
proteases [168]. Another examples for reversible inhibitors are TG2 cofactors, such as GTP and 
GDP; GTP analogues, such as GTPγS and GMP-PCP [169]. 
Figure 1.9. Earliest reversible (allosteric) inhibitor LDN-27219, cynnamoyl based reversible inhibitor Cp4d, 
Compound 15n, acylideneoxoindole based reversible inhibitor Compound 10. modified from [170] 
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1. 7. 2. Irreversible TG2 inhibitors 
Over the course of research many irreversible inhibitors have been developed against TG2. Certain 
electrophilic functional groups that react with the active site nucleophile of the enzyme have 
emerged as privileged warheads. The most portent irreversible inhibitors can be sorted by the class 
of warhead. Halomethyl carbonyl inhibitors, such as iodoacetamide, were one of the first 
irreversible inhibitors tested on TG2, when it was shown that was able to inactivate guinea pig liver 
TG2 [159]. More recently chloromethyl ketones were generated [171], based on a Cbz-Phe scaffold 
[172] (Figure 1.10). 3-Halo-4,5-dihydroisoxazole inhibitors are another group of irreversible 
inhibitors. Acivicin, a natural product of Gln isostere is known to inhibit several cysteine-dependent 
enzymes [173]. By incorporating its 3-halo-4,5-dihydroisoxazole warhead into a Cbz-Phe dipeptide 
scaffold, irreversible inhibitors against TG2 were made [174]. More recently a large series of 3-
bromo analogs were synthesized [175], with he most potent ones optimized with respect to 
stereochemical configuration, aromatic side chain and N-terminal carbamoyl group [176]. These 
compounds were evaluated in vivo and showed good oral bioavailability and efficient extracellular 
TG2 inhibition in small intestinal tissue with toxicity [175].  
Figure  1.10.  Chloromethyl  ketone  based  inhibitor  Compound  5b,  dhydroisooxazole-based  inhibitor 
KCC009, ERW1041E. Avicidin modified from [170].
 28
Introduction
A quinolyl carbamate functionalized (S)-proline compound was also developed, based on a TG2 
specific gluten derived peptide sequence (PQPQPLY) [176] and found to inhibit small intestine 
TG2 activity when tested in a mouse model [177]. Michael acceptors are α,β-unsaturated carbonyl 
derivates that undergo 1,4,-addition reactions. Michael acceptors have been used to inhibit cysteine 
protease [178], some going for human clinical trials for cancer [179]. Irreversible inhibitors with 
acrylamide warhead [171] or acrylamide group on the side chain [180] of the dipeptide scaffold 
were generated and proved to be excellent inhibitors of TG2. Sulfonium inhibitors are bearing a 
dimethyl sulfonium warhead and reported to inactivate epidermal transglutaminase and TG2 [181]. 
The design of these inhibitors was based on the familiar Cbz-Phe scaffold, to which electrophilic 
warhead was attached via a spacer of varied length. A derivate was prepared, bearing an extra 
carboxyl group for enhanced aqueous solubility [144]. These inhibitors which are predominantly 
negatively charged at physiological pH (due to the added carboxylate group), are less favored to 
enter the cell membrane and, therefore rather target extracellular TG2.  
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Chapter 2. Celiac disease 
Celiac disease (CD) is a gluten-sensitive enteropathy that develops in genetically susceptible 
individuals by exposure to cereal gluten proteins. The first description of CD was found in the first 
and second centuries where CD was described as an intestinal disorder associated with diarrhea and 
malabsorption occurring in children and adults. The idea that the disease was linked to food 
ingestion was brought forward in 1888, confirmed in 1950s when Dicke and colleagues established 
that consumption of wheat and rye brought CD and removing these grains from the diet resulted in 
the improvement of the patients condition. In 1954 Paulley [182] reported that the clinical 
manifestation of CD is linked to the destruction of the lining of small intestine. 
It has been revealed that the expression of CD is strictly dependent on dietary exposure to gluten 
and similar cereal proteins [183]. Gluten is the name of wheat proteins only, but it is increasingly 
used to describe proteins of wheat, rye and barley that are rich in proline (Pro) and glutamine (Gln) 
residues. Of gluten proteins, both gliadins (alcohol soluble) and glutenins (alcohol insoluble) are 
harmful [184]. CD can occur at all ages following the introduction of gluten to the diet. Similarly to 
most autoimmune disorders, CD is more frequently (twice as often) found in women than in men 
[185]. CD is primarily the disease of caucasians, affecting 1% of the population [186], most 
frequently recognized among Europeans. The disease exhibits a very strong HLA association, in 
which the relative risk to the disease development for carriers of certain alleles is increased 30 fold 
[187]. Susceptibility is strongly associated with MHC class II molecules HLA-DQ2 and HLA-DQ8 
[188, 189] and the immune response directed against specific gluten antigens leads to the 
destruction of intestinal epithelial cells. CD commonly present in early childhood with classic 
symptoms including chronic diarrhea, abdominal distension and failure to thrive [190]. The disease 
may also present later in life with symptoms that tend to be more vague, including anemia, fatigue, 
weight loss, diarrhea, constipation and neurological symptoms [191]. The celiac lesion is localized 
in the proximal part of the small intestine. The alterations such as villous atrophy, crypt cell 
hyperplasia, lymphocytic infiltration of the epithelium and increased density of various leukocytes 
in the lamina propria characterize one end of a spectrum that has classified into three stages: the 
infiltrative, hyperplastic and the destructive lesions [170]. The infiltrative lesion is characterized by 
the infiltration of small non mitotic lymphocytes in the villous epithelium without any signs of 
mucosal pathology.  
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The hyperplastic lesion is similar to the infiltrate lesion but in addition has hypertrophic crypts 
whose epithelium may be infiltrated with lymphocytes. The destructive lesion is synonymous to the 
classic lesion of CD. Oral challenge experiments with gluten revealed that these stages are 
dynamically related [192]. Patients with CD typically also develop antibodies against gluten and for 
the endogenous enzyme tissue transglutaminase. Despite the fact that gluten is the single causative 
agent, CD can be viewed as an organ-specific autoimmune disease.  
2. 1. Antigen presentation in Celiac disease 
Both genetic and environmental factors contribute to the development of the disease. CD is a 
polygenic disorder with involvement of many genes but the HLA locus encoding human major 
histocompatibility complex (MHC) molecules is far the most important genetic factor contributing 
about 40% of the genetic variance of the disease [193-196]. The primary HLA association for CD is 
conferred by class II HLA-DQ genes. Approximately 90% of CD patients express HLA-DQ2.5 
molecule encoded by DQA1*05/DQB1*02 genes, and the majority of the remaining patients 
express HLA-DQ8, encoded by DQA1*03/DQB1*03:02 genes [188, 197]. If genes encoding the α- 
and the β-chains of the HLA-DQ2.5 heterodimer are carried on the same chromosome (in cis 
position), they are most often found as part of the highly conserved A1-B8-DR3-DQ2 haplotype. 
This particular haplotype is associated with several autoimmune diseases such as type 1 diabetes 
and myasthenia gravis and because of this, sometimes referred to as the “autoimmune 
haplotype” [187]. Patients that are DR5-DQ7/DR7-DQ2 heterozygous also express the HLA-DQ2.5 
molecules, but then the two encoding genes are carried on different chromosomes (in trans 
position). The relevant DQA1 allele (DQA1*05) is encoded by the DR5- DQ7 haplotype and the 
relevant DQB1 allele (DQB1*02) is encoded by the DR7-DQ2 haplotype. There have been 39 non-
HLA loci associated with CD so far, estimated to contribute about 14% of the genetic variance in 
the disease [194, 195]. The relative contribution of each of these genes is minor compared to the 
HLA genes. Many of the non-HLA polymorphisms seem to act by influencing gene expression 
[195]. Furthermore, many non-HLA CD risk loci are shared with other immune-related diseases, 
such as type 1 diabetes and rheumatoid arthritis [198-201]. The shared genetic background among 
these diseases points to common pathogenic pathways in them [202]. In CD different HLA types 
associated with the disease have been shown to bind proline rich gluten peptides that harbor 
glutamic acid, however all HLA types have distinct peptide binding preferences (Figure 1.11.).  
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Figure 1.11. HLA-DQ2.5 and HLA-DQ2.8 present different type of gluten peptides. HLA molecules 
bind proline-rich gluten peptides that harbor glutamic acid residues (E). A. HLA-DQ2.5 presents a high risk 
for CD and bind peptides deamidated at positions P4 and P6. B. HLA-DQ8 low risk variant prefers binding 
gluten peptides with deamidation at position P1 or P9. [203] 
Gluten peptides have preferred binding to DQ2.5 molecules compared to other HLA class II 
molecules [204]. Peptide binding studies have shown that contact between DQ2.5/DQ8 and the side 
chains of the peptides, so-called anchor residue and pocket interactions, takes place at the P1, P4, 
P6, P7, and P9 position [205-208]. Peptides that bind HLA-DQ2.5 preferentially have deamidation 
at positions P4, P6, and occasionally P7, whereas peptides binding HLA-DQ8 have negatively 
charged residues at P1and/or P9 [209]. To date, more than 15 different gluten-derived T-cell 
epitopes have been reported in CD [210-212] and all contain a deamidated residue in at least one of 
these pocket positions. The great majority of these T-cell epitopes contain glutamine residues that 
are targeted by TG2 and converted into glutamate residues by a deamidation reaction. In general T 
cells of celiac disease patients recognize deamidated epitopes with greater efficiency than native 
ones. This effect of PTM appears to be stronger for HLA-DQ2.5 restricted epitopes than for HLA-
DQ8 restricted epitopes, as many of the HLA-DQ2.5 restricted epitopes are not recognized in their 
native form whereas some HLA-DQ8 restricted epitopes are equally well recognized as native 
peptides [213]. 
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There is a correlation between how frequently T-cell epitopes are recognized by CD patients and 
their propensity to be targeted as substrates for TG2 [214] (Figure 1.12.). The idea that TG2 is one 
of the most important factor selecting gluten T-cell epitopes is supported by an experiment where 
TG2 was used to select peptides from a proteolytic digest of gluten containing several thousand 
different peptides [215]. Peptides, which were targeted by TG2, were purified and sequenced. 
Strikingly, of 31 selected peptides, more than 75% contained celiac disease related T-cell epitopes. 
The negative charges introduced by the TG2-mediated deamidation increase the binding affinity of 
gluten peptides to HLA-DQ2.5 and HLA-DQ8. Majority of extracellular TG2 is inactive, however 
it can be transiently activated by certain types of inflammation or injury signals [216].  
 
Figure 1.12. Pathogenesis in celiac disease. A, TG2 mediates the post-translational modifications of gluten 
peptides which in turn are presented on the surface of HLA molecules to T cells. In turn, the generation of 
antibodies start against gluten and TG2. B, TG2 mediated deamidation turns the protein bound, neutral 
glutamine into negatively charged glutamate which can be presented on the surface of HLA molecules. 
modified from [217] 
The enzymatic activity of TG2 is found to be tightly regulated by the redox potential of the 
environment, mediated by a redox-sensitive cysteine triad consisting of Cys230, Cys370, and Cys371 
[218]. TG2 has been shown to reversibly inactivated by oxidation, however Ca2+ can protect the 
enzyme from oxidation and inactivation.  
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In a model of TG2 activation, TG2 is released extracellular matrix upon cell wounding and remains 
catalytically active for a short period of time but then becomes silenced through oxidation. A change 
in the reductive environment may rescue TG2 from inactive state as it happens when ongoing 
immune reactions alter the redox state of lymphoid tissue. The thiol content is increased after 
antigen stimulation, particularly in mesenteric lymph nodes after intraperitoneal immunization 
[219]. An ongoing immune response, including those directed against infectious agents, may thus 
facilitate TG2 activity and an immune response to deamidated gluten. Because of its high Pro 
content gliadin is remarkably resistant to luminal and brush border proteolysis and large fragments 
remain intact after digestion. The most illustrative fragment is the 33-mer produced by the 
digestions of certain α-gliadin proteins. The 33mer fragment remains intact even after extended 
incubation with gastric, pancreatic, and intestinal brush-border membrane enzymes [220]. It 
contains six overlapping copies of two different DQ2.5-restricted T-cell epitopes and is recognized 
by T-cell lines from nearly all adult CD patients. The two epitopes contained within this 33mer 
peptide, the DQ2. 5-glia-α1 and DQ2.5-glia-α2 epitopes, are often referred to as the dominant T-cell 
epitopes in CD. Intriguingly, the 33mer peptide can bind DQ2.5 molecules directly on the surface of 
APCs and can thus be presented to T cells without further intracellular processing [221]. The 
gliadin-derived epitopes cluster in the Pro-rich regions of gliadin, a property that both confers 
relative proteolytic resistance and favors TG2-mediated deamidation [210].   
The  adaptive  immune  response  is  initiated  by  APCs,  primarily  dendritic  cells  (DCs)  but  also 
macrophages and B cell subsets, which present to T-cell antigenic fragments in complex with cell 
surface MHC class II molecules. This antigen priming usually takes place in organized lymphoid 
tissues.  APCs  travel  from  peripheral  tissues  to  lymph  nodes  where  they  generate  effector  or 
tolerogenic  T  cells  that  operate  in  the  peripheral  tissues.  The  re-activation  of  effector  and 
tolerogenic  T  cells  in  peripheral  tissues  will  again  require  interaction  with  APCs.  Antigen 
presentation is a key initial step during the pathogenesis of CD both in mesenteric lymph nodes and 
the intestinal lamina propria. 
Macrophages are tissue-resident cells that differentiate from circulating monocytes [222, 223]. 
These cells are long-lived with low turnover in the tissue. They occupy the cellular zone beneath the 
enterocytes and also can be found scattered in the lamina propria. Human jejunal macrophages have 
been reported to have a decreased capacity to produce cytokines and do not express receptors 
typical for innate immune responses.  
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The role of activated macrophages in CD is elusive, since they were not found to be effective 
presenters of gluten peptides to gluten reactive T-cell clones [224]. However activated macrophages 
may play role in the pathogenesis by producing cytokines. In contrast to macrophages DCs are 
messenger cells with a rapid turnover. Precursors of DCs have not yet been described in the human 
blood, but three distinct cell subsets may generate tissue DCs: monocytes, classical myeloid DCs, 
and plasmacytoid DCs.  
The two main subgroups of DCs, myeloid and plasmacytoid DCs, are characterized respectively by 
their abilities to prime naïve T cells and to secrete large amounts of IFN-α in response to viral 
infections. In the lamina propria of patients with CD, the density of classical myeloid DCs is 
reduced [225]. Lower tissue density may be due to inflammation-induced expansion of the tissue 
volume. Another plausible scenario is that genuine cell depletion is due to migration to lymph 
nodes, diminished recruitment, cell death, or a combination of these events. Human plasmacytoid 
DCs (PDCs) typically reside in lymphoid tissues and rarely infiltrate inflamed tissues. Plasmacytoid 
DCs residing in the mesenteric lymph shown to induce mucosal T-cell-independent IgA synthesis 
through the cytokines APRIL and BAFF [226]. Plasmacytoid DCs probably do not migrate in 
intestinal or hepatic lymph, distinguishing these cells from myeloid DCs that carry intestinal 
antigens to mesenteric lymph nodes [227]. Plasmacytoid DCs are producers of IFN-α which has 
been reported to induce development of CD. This finding supports their role in the pathogenesis of 
the disease. Intermediate dendritic cells are a subset of antigen presenting cells in the normal 
duodenum [225]. These cells have an intermediate phenotype and express markers typical for both 
DCs and macrophages. In mice intermediate DCs appear to originate from monocytes rather than 
DC precursors and believed to be tissue resident cells playing an important role in modifying local 
immune responses. Several lines of evidence suggest that intermediate DCs play a direct role in the 
pathology of CD. Unlike classical DCs and macrophages that show a decrease in the tissue 
concentration, the density of these cells increases after 3-day gluten challenge of CD patients. 
Beyond this, the increased density of intermediate DCs proceeds the typical inflammation related 
changes of the intestine and the surge of intraepithelial lymphocytes and eosinophils, suggesting 
that they have a role in the initiation of CD [228]. These findings indicate a plausible scenario 
where myeloid DCs traveling from the tissue to the mesenteric lymph nodes, carry gluten antigens 
and inflammatory signals for priming the naive T-cells into effector T-cells.  
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This causes a depletion of myeloid DCs in the lamina propria. In the other hand an influx of blood 
monocytes that differentiate into intermediate DCs can be observed in the. These cells mediate the 
reactivation of memory T cells in the intestinal mucosa. B cells likely play a role as antigen 
presenting cells in the mesenteric lymph nodes for the amplification of gluten T cell response. 
2. 2. T cell response in Celiac Disease 
CD4+
 
T cells that recognize gluten peptides can readily be isolated from biopsies of CD patients, but 
not from individuals without the disease [229, 230]. These T cells recognize epitopes of gluten 
presented by disease associated HLA-DQ molecules [231, 232]. The MHC association in CD is 
linked to the preferential binding by HLA-DQ2 and HLA-DQ8 molecules to the proteolysis 
resistant gluten peptides that have negatively charged glutamate residues introduced by TG2 [220, 
233-235]. Moreover, it has been proposed that gluten peptide-MHC complexes, expressed on the 
surface of antigen presenting cells are defining the magnitude of the gluten-specific CD4+ T cell 
response and consequent induction of intestinal tissue damage [236]. This was based on a finding 
that susceptibility to CD is higher for those individuals who are homozygous for HLA-DQ2 or 
HLA-DQ8 alleles [237]. Unlike in healthy individuals, CD4+
 
T cell responses to dietary gluten in 
the small intestinal mucosa can be observed for CD patients [230] (Figure 1.13). In CD an alteration 
in the intestinal environment can be observed which affects the differentiation/function of forkhead 
box P3 FOXP3+ TReg cells. FOXP3 cells are responsible for oral tolerance [238] by secretion of anti-
inflammatory cytokines such as transforming growth factor-β (TGFβ), IL-10 and IL-4 and promote 
the production of IgA antibodies [239].  
 36
Introduction
Figure 1.13. In the pathogenesis of CD gluten-specific CD4+ T helper 1 (TH1) cells secrete pro-
inflammatory mediators such as interferon-γ (IFNγ) or interleukin-21 (IL-21), which promote activation of 
intraepithelial cytotoxic T lymphocytes (CTLs) and block the inhibitory effects of forkhead box P3 
(FOXP3)+ T Reg cells. In addition, gluten-specific TH1 cells help B cells to produce gluten- and TG2-specific 
IgG and IgA antibodies [240]. 
The intestinal mucosa in CD is characterized by presence of high levels of pro-inflammatory 
cytokines such as IL-15 [241-243] and IFNα [244-246]. It has been observed that in HLA-DQ8-
transgenic mice IL-15 is able to alter the phenotype of intestinal DCs and prevent the activation of 
FOXP3+Treg cells after oral challenge with gluten. Based on these observations it has been proposed 
that intestinal DCs when stimulated by pro-inflammatory factors as IL-15 or IFNα might loose their 
tolerogenic phenotype, promoting the differentiation of pro-inflammatory T cells. Beyond this 
effect IL-15 was shown to prevent the inhibitory effect of TGFβ [247] supporting that effector T 
cells in the gut mucosa of CD patients might be insensitive to the regulatory effect of TGFβ and 
FOXP3+ TReg cells. CD4+ T cells have been implicated to help to set up the inflammatory 
environment which allows the intraepithelial cytotoxic T lymphocytes (CTL) to induce tissue 
damage. By the secretion of pro-inflammatory cytokines such as IFNγ and IL-21, which may 
promote epithelial cell destruction by intraepithelial CTL activation. After activation by IL-15, 
intraepithelial CTLs were reported to expand early in the disease process [248], leading to the 
destruction of intestinal epithelial cells and villous atrophy [249, 250]. In humans CTLs has been 
shown to express the activating receptor NKG2D [251].  
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Expression of this receptor conferred potent co-stimulatory and direct cytotoxic functions on the 
CTLs, in particular following stimulation with IL-15 [252]. In healthy individuals, intraepithelial 
CTLs express the inhibitory receptor CD94–NKG2A, the C-type lectin CD161 and low levels of the 
activating receptors NKG2D and CD94–NKG2C [253] by contrast, intraepithelial CTLs from 
patients with celiac disease lose their expression of the inhibitory receptor CD94–NKG2A and 
acquire high levels of expression of the activating receptors NKG2D and CD94–NKG2C. In 
addition, IL-15, produced by intestinal epithelial cells in patients with celiac disease, has recently 
been shown to induce signaling in CTLs and can alter their function, in particular by up regulating 
the expression of NKG2D and co-stimulating the NKG2D cytotoxic signaling pathway [254].  
Activation of intraepithelial CTLs by NKG2D and IL-15 could therefore not only contribute to the 
destruction of intestinal epithelial cells but also promote nonspecific inflammation in the intestinal 
mucosa of patients with celiac disease. Intraepithelial CTLs in patients with celiac disease were also 
proved to undergo a profound genetic reprogramming of NK cell functions, becoming NK cell-like 
cells. This NK cell-like transformation of intraepithelial CTLs may be a crucial step that precedes 
refractory sprue and enteropathy-associated T cell lymphoma (EATL), which are rare but major 
complications of celiac disease that are characterized by the presence of high numbers of 
intraepithelial CTLs with a NK cell-like phenotype and persistent villous atrophy despite a gluten-
free diet [255, 256]. It is a plausible scenario that chronic NKG2D activation participates in NK cell 
reprogramming and malignant transformation of CTLs in CD. Although intraepithelial CTLs in 
celiac disease seem not to be specific for gluten, they respond to the indirect effects of gluten that 
cause up regulation of IL-15 and non-classical MHC class I molecules on intestinal epithelial cells.  
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2. 3. Antibody response in Celiac disease 
In addition to T cells reactive to gluten, CD patients produce antibodies specific for gluten and TG2 
[257]. These antibodies are excellent markers for celiac disease, as both anti-gluten and anti-TG2 
antibodies disappear from the circulation within months after the introduction of gluten-free diet 
[258, 259]. Serologic testing for CD specific antibodies has become increasingly important tool in 
the diagnostic workup of patients. The first serologic tests were developed 50 years ago based on 
anti-gliadin antibodies binding to native gliadin antigen [260, 261], but these tests showed relatively 
poor sensitivity and specificity. In 1997, TG2 was identified as the antigen recognized by anti-
reticulin and anti-endomysium antibodies, leading to the development of diagnostics test measuring 
serum anti-TG2 antibodies by ELISA [262]. At the moment, anti-TG2 antibodies serve as the most 
specific and sensitive marker for active CD and their detection is the preferred diagnostic tool [263, 
264]. New tests to detect IgG anti-gluten antibodies using synthetic deamidated gliadin peptides as 
substrates perform almost as well as the IgA anti-TG2 test [259] and proved to be especially useful 
in the diagnoses of infants and IgA-deficient patients [265]. This paragraph will dissect the anti-
gulten B-cell response while the autoantibody response against TG2 will be discussed in the next 
chapter. The epitopes recognized by gluten-reactive CD4+ T cells of CD patients include glutamate 
residues, which have been introduced by TG2-mediated deamidation of certain glutamine residues 
[215]. Gluten B-cell epitopes have been characterized by studying polyclonal serum antibody 
reactivity to synthetic peptides of gliadin proteins [266] and by bacterial cell-displayed peptide 
libraries [267]. Deamidation is also relevant for the B-cell epitopes, and serum antibody reactivity is 
higher to deamidated than to native (non-deamidated) peptides [266, 268]. Gliadin B-cell epitopes 
appear to be located in proximity and/or to overlap with gliadin T-cell epitopes IgA antibodies to 
gliadin only occur in subjects with HLA-DQ2 or HLA-DQ8 [269]. The HLA dependence of the 
antibody production and the colocalization of T-cell epitopes and B-cell epitopes suggest that the 
antibody response to gluten in CD is T cell dependent. In a recent study, gluten (gliadin)-reactive 
antibodies expression was characterized by cloning IgA+ PCs isolated from small intestinal biopsies 
[270]. Antibodies had a limited number of somatic hyper mutation (SHM) which is common feature 
with IgA antibody responses to gluten and TG2 in CD. This suggests that the factor(s) causing the 
limited SHM in IgA of gliadin specific PCs is likely involved in both antibody responses. Anti TG2 
and anti-gliadin antibodies have a parallel fluctuation [258] suggesting that the production of these 
antibodies is regulated in a coordinated way.  
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It has been suggested that gluten-specific T cells could provide help to TG2-specific B cells. 
Gluten-specific T-cells may also provide help to gluten-specific B cells. As gluten-specific T cells 
preferentially recognize deamidated gluten peptides, B cells with surface immunoglobulin that bind 
and internalize deamidated gluten peptides would be better situated to receive T-cell help. Some 
anti-gliadin antibodies are specific to deamidated gliadin peptides and do not recognize non-
deamidated counterparts, indicating that gliadin-specific B cells must have encountered deamidated 
gliadin [270]. Gliadin specific antibodies have also been reported to cross-react with different 
gliadin peptides [270] and display several different T-cell epitopes. This could lead to B cells 
receiving help from several different T-cell clones, as recently described [271]. In addition to the 
limited SHM, a restricted VH/VL usage was observed in the panel of gluten-specific antibodies 
with he same VH/VL pairings appearing in different subjects. Limited VH usage is a sign of T-cell-
dependent responses [272]. The restricted VH/VL usage also raises the possibility that might be 
genetic effects at the immunoglobulin loci for the development of this disease.  
2. 4. TG2 specific autoantibody response 
2. 4. 1. TG2 specific antibody production and response to gluten 
In addition to gluten reactive T cells, CD patients produce antibodies specific for gluten and self 
antigen TG2 [257]. In 1997 TG2 was identified as the antigen recognized by anti-reticulin and anti-
endomysium antibodies [262], however antibodies specific for other autoantigens as actin, collagen 
have also been described [273]. In addition of the massive CD4+ T-cell response toward deamidated 
gluten, the celiac lesion is characterized by the expansion of plasma cell (PC) population [274, 275] 
and enhanced local immunoglobulin secretion [276, 277]. The specific antibody response against 
TG2 in the serum has become the most sensitive and specific serological assay used fro the 
diagnosis of CD [263]. Upon commencement of gluten free diet anti-TG2 antibody titer drops 
below the cut off value within six month [278]. Following a short term gluten challenge they 
reappear in the in the blood within 2-4 weeks [279]. Serum titers of anti-TG2 antibodies seem to 
correlate with intestinal damage [280], however antibodies can be detected in patients with no 
histological findings [281-283].  
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It was possible to visualize TG2-specific antibodies in the duodenal mucosa of CD patients [284]. 
TG2 specific antibodies can be found as IgA deposits in the basement membrane of small intestine 
[285] and these deposits are present even in the absence of detectable anti-TG2 serum level serving 
a predictive value for the disease [281]. This indicates that anti-TG2 antibodies appear at an early 
stage of CD and TG2 specific B-cells are activated in response to dietary gluten prior to any clinical 
symptom. Phage display libraries of single chain antibody variable regions obtained from the IgA 
producing intestinal biopsy lymphocytes and peripheral blood lymphocytes of CD patients were 
used to study the antibody response in CD [286]. It was possible to isolate anti-TG2 antibodies from 
intestinal lymphocytes libraries but not from those generated from peripheral lymphocytes. This 
indicates  that  the  response against  TG2 occurs  at  a  local  level  in  the  small  intestine  and their 
presence in the serum is attributable to spill over into the blood compartment. These antibodies 
target the same antigen in the extracellular matrix and endothelium of small blood vessels [285], 
supporting the local antibody production. 
2. 4. 2. Biased V gene usage and limited somatic hypermutations of Abs
Analysis of the TG2 specific antibody repertoire from single chain immunoglobulin phage display 
libraries from intestinal biopsies [286] revealed that VH gene usage was restricted to three (VH 5, 
VH 3, VH1) of the seven human Ab VH families with a biased usage VH5 family gene segment 
among IgA producing cells. The preference was not found in naive B-cell library indicating that 
VH5 family  selection  is  not  due  to  the  intrinsic  TG2 affinity  associated  with  the  heavy chain 
variable region. Recombinant antibodies has been generated from the single plasma cells of celiac 
patients. It was found that TG2 specific PCs represent 5-25% of total PCs in the celiac lesion [284, 
287].  The  PCs  had  strong  bias  in  their  VH  and  VL usage  with  a  preference  of  IGHV5-51, 
IGHV3-48, IGHV4-59, IGHV1-69, IGKV1-39, IGKV1-5  with a dominance of IGVH5-51. It was 
found that 44% of TG2 specific antibodies were encoded by IGHV5-51 family. It is an important 
feature that a number of IGHV5-51 antibodies with different specificity did not bind TG2, thus 
showing that the anti-TG2 reactivity is encoded by CDR and not depends on the unspecific binding 
of the VH5 framework region [284]. The biased usage of certain genes in antibody response has 
been  observed  in  other  autoimmune  diseases  such  as  rheumatoid  arthritis  [288]  and  also  in 
responses towards foreign antigens such as HIV [289] and influenza [290]. In spite the extensive 
switch  to  IgA anti-TG2 antibodies  also  have few somatic  hypermutations  [284],  less  than half 
amount of mutations were observed compared to the rest of the intestinal PC compartment. 
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This is in contrast to what is observed in IgA responses toward pathogens such as influenza and 
rotavirus [284, 291] and also in autoimmune diseases such as rheumatoid arthritis [288]. Reversion 
of mutated anti-TG2 antibody sequences into presumed germline configuration leads to reduced 
affinity of antibodies, indicating that the affinity maturation happens during the generation of these 
antibodies [284]. The fact that none of the anti-TG2 antibodies have polyreactivity indicate that 
TG2 reactive B-cells recognizing the antigen with high specificity and reasonable affinity must exist 
in  the  naive  B-cell  repertoire  of  CD patients.  Gut  derived TG2 specific PCs have a  small  but 
detectable memory compartment [284] which is supported by the fact that TG2 reactive PCs in the 
small intestine do not disappear completely in gluten free diet indicating that al least a number of 
the PCs are long lived as also observed in in vitro culture [284, 292] 
2. 4. 3. Targeted epitopes of anti TG2 antibodies
Epitopes recognized by TG2 specific antibodies are known to be conformational, and a study with 
polyclonal sera of CD patients indicated that there is an important conformational epitope which 
was targeted by both serum antibodies and tissue-derived monoclonal antibodies [293]. In contrast, 
TG2 antibodies from subjects with other autoimmune diseases preferred other binding sites. The 
main anchors points of this celiac epitope reported to be Glu153 and Glu154 on the edge of the first 
alpha helix of the core domain of TG2, but they also need one more anchor point either on the N-
terminal or C-terminal domains (Figure 1.14.). The N-terminal anchor point is formed by the first 
helix containing Arg19 while the anchor point Met659 can be found on the C-terminal domain.  
Figure 1.14. Three-dimensional view of TG2 in the closed conformation with the N-terminal β-sandwich 
shown in blue, catalytic (core) domain in red, β-barrel 1 in cyan and β-barrel 2 in pink. The amino acids of 
the putative celiac epitope with their lowest distances in angstroms (Å) are illustrated as represented on 
surface. [293] 
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Epitope mapping studies revealed that TG2 specific antibodies target at least four different epitopes 
clustered in the N-terminal of TG2 [ 294] (Figure1.15). These epitopes were also represented 
among the polyclonal anti-TG2 IgA antibodies present in the serum. Epitope recognition correlated 
with the VH usage, epitope 1. antibodies mainly used VH5 gene segment, epitope 2 antibodies used 
VH3 segments and epitope 3 antibodies used mainly VH4 gene segments [294]. Antibodies 
representing each epitope cluster were tested for their ability to stain cell surface TG2 (csTG2) 
expressed on the surface of immature dendritic cells (iDCs). None of the antibodies were able to 
stain suggesting that the epitopes are hidden when TG2 is expressed on cell surface. It was also 
revealed that the region recognized by epitope 1. antibodies is overlapping with the fibronectin 
binding site of TG2 [71, 294]. A more recent study by hydrogen/deuterium exchange and 
subsequent mutational analysis of TG2 demonstrated that residues Lys-30 and Glu-8 are part of 
epitope 1., while Arg-19 is part of epitope 2 [295]. The binding interface of antibodies and TG2 was 
further analyzed by small angle x-ray scattering, ab initio and rigid body modeling using the known 
crystal structure of TG2 and an epitope 1. antibody Fab fragment. The results, which were 
supported by ELISA made on TG2 point mutants, implicated that Arg-116 and His-134 are critical 
for binding epitope 1. antibodies, but not for epitope 2 and epitope 3. antibodies [296].  
Figure 1.15. Regions targeted by TG2-specific autoantibodies. Surface representation of the open TG2 
structure with a bound active site inhibitor shown in green. The region in the N-terminal domain implicated 
in binding FN representing epitope 1/4 is shown in red. The region representing epitope 2/3 is shown in cyan.
[294] 
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2. 4. 4. Collaboration of TG2 specific B-cells and gluten specific T-cells in CD 
TG2 specific autoreactive B-cells may receive help from gluten specific T-cells as stated in the most 
widely accepted, ‘hapten carrier model’ [297] (Figure 1.16). The model relies on the fact that TG2 
specific B-cells are able to internalize gluten T-cell epitopes by taking up TG2-gluten complexes 
through B cell receptor (BCR) mediated endocytosis. Two types of covalently linked complexes of 
gluten peptides and TG2 can be formed: either by coupling to the active site cysteine via thioester-
bond or by coupling to surface exposed lysine residues via isopeptide-bonds [298]. The lysine 
residues of TG2 which are involved in forming isopeptide-bonds are predominantly situated on the 
C-terminal part of the molecule, leaving the N-terminal part recognized by TG2 specific B-cells 
untouched [299]. Internalization of gluten-TG2 complexes is followed by endosomal processing 
and presentation of gluten peptides on MHC class II molecules on the cell surface to gliadin specific 
T-cells. This would result in TG2 specific B-cells receiving activation signals from CD4+ T-cells. 
The uptake of TG2 cross-linked to a variety of different T-cell epitopes could provide TG2 specific 
B-cells help from T-cells with different specificities. The model is supported by that TG2 specific 
antibodies rapidly disappear when gluten is removed from the diet [258, 300]. In addition the strict 
HLA dependence of the antibody response strongly implies the involvement of T-cells. A population 
based study on Swedish children compared the presence of TG2 specific antibodies in individuals 
with or without DQ2 or DQ8 HLA-risk alleles [269], and found that TG2 specific antibodies are 
only detectable in those who are having specific HLA types associated with CD.  
Another possible scenario for activation of TG2 specific B-cells relies on TG2 utilizing the BCR as 
a substrate for covalent cross-linking of gluten peptides [301] (Figure 1.16). TG2 cross-links 
peptides to TG2 specific BCR of the IgD but not to the IgA isotype, with a preference to IGHV5-51. 
It is know that cross-linking of BCRs or covalent linkage of antigen stimulate B cell activation 
[302], indicating a plausible scenario for activation of naive TG2-specific B-cells compared to 
isotype-switched IgA- or IgG-expressing memory B cells. The model could explain the preferential 
usage IGHV5-51 and the limited number of somatic hypermutations. 
 44
Introduction
Figure 1.16. Models for activation of disease specific B cells by gluten specific CD4+ T cells in CD. Gluten 
T-cell epitopes (shown in green) are deamidated ( shown in red) by TG2, and overlap with or are in close 
proximity to gluten B-cell epitopes (blue). TG2-specific B cells may internalize gluten T-cell epitopes 
through BCR mediated uptake of TG2, with gluten transiently bound to the active site (1) or through uptake 
of isopeptide linked TG2-gluten complexes (2). Gluten-specific B cells preferentially bind long, multivalent 
peptides (3). Multivalent TG2-gluten complexes may cross-link the BCRs of both TG2-specific B cells (2) 
and gluten-specific B cells (4). In addition, gluten T-cell epitopes may be cross-linked directly to the TG2 
specific BCR (5). 
The model requires that TG2 remains active when bound to the BCR. From 47 antibodies generated 
from single intestinal PCs of CD patients none had inhibitory effect on TG2 enzymatic activity 
[284]. A contradictory data was shown with IgA and IgG antibodies purified from CD patients, the 
IgG antibodies showing inhibition between 8.3-24% and IGA antibodies having 11.1-39% 
inhibition over TG2 enzymatic activity [303]. The experiment repeated with monoclonal antibodies 
derived from the intestinal lymphocytes of CD patients had the same result with an inhibitory effect 
ranging from 20% to 40%. Apart from the providing a possible explanation for the gluten-
dependent production of TG2 specific B-cells, the hapten carrier model propose a plausible scenario 
where TG2 specific B-cells act as antigen presenting cells for gliadin specific T-cells and this way 
contribute to the pathogenesis of CD. There has been speculations whether the antibodies 
themselves are pathogenic. 
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2. 4. 5. Pathogenic roles of anti TG2 antibodies
Celiac disease is hallmarked by increased small-intestine epithelial cell proliferation and decreased 
differentiation.  It  has  been  shown  that  anti-TG2  antibodies  inhibit  intestinal  epithelial  cell 
differentiation and also increase the permeability  of  the  intestinal  epithelial  cell  [304-306]  The 
conception of anti-TG2 antibodies being pathogenic is further supported by studies performed on 
CD patient  small-bowel  biopsy  organ  culture  suggesting  that  patient  IgA enhances  passage  of 
gliadin peptides into the lamina propria [307]. Patient IgA induced gliadin translocation into the 
tissue could promote the development of small-intestinal damage by enabling and amplifying the T-
cell response. Anti-TG2 IgA antibodies also may detach TG2 from fibronectin and the complexes 
could be transported across the epithelium where TG2 or the antibodies themselves contribute to the 
sampling  of  gliadin  peptides.  This  model  is  supported  by  the  fact  that  epitope  1.  anti-TG2 
antibodies recognize the fibronectin binding site on TG2 [294]. Anti-TG2 autoantibody deposits are 
located  around  the  mucosal  blood  vessels  in  the  small-bowel  in  patients  with  CD  [285]  and 
considering the fact that they have been show to inhibit angiogenesis in vitro [308, 309] they might 
contribute to the aberrant organization of the mucosal vascular network. Anti-TG2 antibodies have 
been reported to increase blood vessel permeability to both macromolecules and lymphocytes in 
vitro and this effect could potentiate the small-bowel mucosal inflammatory response by enhancing 
the invasion of lymphocytes and macromolecules into the small intestine.
Celiac  disease  is  occasionally  reported  to  manifest  in  the  nervous  system including  peripheral 
neuropathy, epilepsy and cerebral ataxia [310]. Gluten ataxia is a sporadic cerebellar ataxia with 
majority of the patients with enteropathy having circulating anti-TG2 antibodies [311]. It has been 
reported  that  all  gluten  ataxia  patients,  even  seronegative  had  IgA-class  anti-TG2  antibodies 
deposited in the small intestinal mucosa and the antibodies were also present in brain vasculature of 
a gluten ataxia patient [312]. The passive transfer of anti-TG2 antibodies derived from CD patient 
to the mouse brain has been reported to cause ataxia like symptoms in the recipient animals [313]. 
These data suggest that anti-TG2 antibodies might lead to the neurologic pathologies occurring in 
association with CD. Celiac disease has been associated with a wide range of reproductive disorders 
in women. A shorter duration of fertile life spam in women with untreated CD because of an older 
age  of  menarche  and  younger  age  of  menopause  and  an  increased  prevalence  of  secondary 
amenorrhea have been shown in several studies [314, 315]. 
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The length of the reproductive period seems to correlate with the state of CD since studies have 
shown that celiac women of long term GFD show a duration of fertility life spam analogue to 
healthy women [314, 316]. The mean number of children born from celiac patients is significantly 
less compared to healthy controls and the overall difference in fertility is due to an infertility period 
in  celiac  women [315].  Anti-TG2 antibodies  have  been implied  in  placental  related  pregnancy 
complications. It has been demonstrated that TG2 is expressed in endometrial cells as well as in 
stromal and trophoblast cells with higher level in late pregnancy[317]. Since extracellular TG2 is 
involved  in  cell  adhesion  and  migration  [66,  318]  it  is  likely  to  play  a  critical  role  in  the 
implantation  process.  TG2  on  syncytiotrophoblasts  may  be  the  target  of  maternal  anti-TG2 
antibodies in CD. Anti-TG2 antibodies of IgA class have been reported to bind to the syncytial 
surface of placenta and inhibit TG2 activity [319], explaining the functional impairment of placental 
development. It has been demonstrated that polyclonal fractions of anti-TG2 antibodies as well as 
the monoclonal anti-TG2 antibody were able to directly bind to trophoblast cells and significantly 
reduce  trophoblast  invasiveness  through  apoptotic  damage  [320].  Beyond  these  findings  a 
significant decrease in MMPs activity was observed in the study which could be an indirect effect of 
the  increase  in  trophoblast  apoptosis.  After  the  stimulation  of  angiogenic  factors  the  basement 
membrane is degraded by MMPs and proteolytic enzymes secreted by endothelial cells allowing 
cells to invade, migrate and proliferate into the underlying interstitial matrix and form new capillary 
structures [321, 322]. The angiogenesis induces crucial changes in the endometrium, enabling it to 
accept blastocysts and initiate implantation. Anti-TG2 antibodies have been implicated to interfere 
in the endometrial angiogenesis. IgA and IgG polyclonal immunoglobulins isolated from the sera of 
celiac patients as well monoclonal anti-TG2 antibody have been reported to bind the membrane of 
human endometrial endothelial cells (HEECs) isolated from placental explants [323]. The binding 
was  followed  by  a  significant  decrease  of  in  vitro  angiogenesis.  The  mechanism  causing  this 
decrease was investigated and a significant level of reduction of both pro- and active MMP-2 level 
was  observed.  These  data  suggest  a  plausible  scenario  of  anti-TG2  antibodies  inhibiting 
angiogenesis by reducing MMP secretion and this way extracellular matrix degradation. A dramatic 
disarrangement in the F-actin cytoskeleton in the anti-TG2 antibody treated cells have been reported 
[324, 325].  FAK and ERK are key kinases of the intracellular pathway regulating cytoskeleton 
rearrangement and the transcription of pro-angiogenic factors [326, 327]. Anti-TG2 antibodies have 
been demonstrated to inhibit FAK and ERK providing this way another mechanism how they inhibit 
angiogenesis in endometrial cells [328].
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Chapter 3. Expression libraries
Gene expression technologies are important tools for the study of expression profiles of a great 
variety of biological systems. These technologies provide a direct physical association between 
phenotype (protein under analysis) and genotype (gene encoding the protein). Expression libraries 
are used for two main goals in research, to screen at the same time thousand of proteins expressed 
by the library and to detect such characteristics as interaction, sensitivity even when the interactors 
in the biological sample or the proteins of the library are present in low level. cDNA libraries are 
the most common source of DNA for screening approaches. These libraries are prepared from the 
total single-stranded mRNA extracted from human tissue as well as other organisms such as plants 
or yeast [329-333]. The single-stranded mRNA is converted into double-stranded DNA by the 
enzyme reverse transcriptase. After this step the cDNA fragments can be cloned to an appropriate 
vector, where the final population of vectors will represent the entire set of genes expressed in the 
source of mRNA. A number of formats can be used to study the complex mixture of proteins. 
Bacterial systems, such as E. coli are preferred because of their ability to grow rapidly and high 
density on inexpensive substrate, well-characterized genetics and availability of cloning vectors 
[334]. In spite of these advantages bacterial systems might have problems in expressing eukaryotic 
proteins due to aggregation, formation of inclusion bodies and the lack of post-translational 
modifications [335]. Eukaryotic systems, such as baculovirus system [336] overcome these 
drawbacks, however have issues such as lower yield, high demands of sterility and time consuming 
cloning procedures. cDNA libraries can be tested by PCR, DNA hybridization [337], two-hybrid 
systems [338], enzymatic activity [339], high-throughput structure determination [340], and by 
recognition by antibodies [341].  
3. 1. Display systems 
Display systems allow us to create libraries of biomolecules and to screen them for certain 
characteristics in a high throughput format.This approach not only makes possible to analyze 
protein-protein, protein-substrate interactions, but also to isolate antibodies for the desired antigen. 
Complex libraries can be enriched by selection strategies for clones with the desired specificity. The 
advantages of the method is that selected proteins can be rapidly identified by DNA sequencing and 
manipulated by molecular biology techniques. 
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3. 1. 1. In vitro display systems 
Ribosome and RNA display are in vitro display systems, where genes are coupled to the proteins 
they encode after a translation step in an in vitro translation mix. These display systems rely on 
PCR for amplification and in vitro translation of RNA to produce the binding ligand, which is 
attached to the encoding RNA. In RNA display the RNA is covalently linked to the encoded protein 
by a puromycin adaptor, while in ribosome display the gene and the encoded protein are non-
covalently linked by the ribosome itself [342, 343]. These methods allow size as large as 1015 
different members increasing the probability to select rare sequences and to improve the diversity of 
the selected ones. In vitro selection methods overcome such problems as poor protein expression 
and protein degradation which might reduce the diversity of selected sequences.  
3. 1. 2. Cell based display systems 
In cell based display systems such as phage and yeast display the amplification, display and 
coupling of genotype and phenotype is carried out by living organisms. Phage display in the oldest 
and the most widely used cell based display system. In this system a large number of genes are 
cloned upstream the coat protein gene and displayed on the surface fused to the coat protein of the 
filamentous phage. This system will be described in detail in the next paragraph. The yeast cell 
provides the linkage as the protein of interest is expressed as a fusion to a cell wall protein. 
Different yeast strains and cell surface receptors have been used for cell surface display, however  S. 
cerevisiae Aga2p system remains the most commonly used. In this system, proteins are expressed 
as cell surface fusions to theAga2p subunit of the mating protein a-agglutinin in S. cerevisiae. 
3. 2. Selection methods 
3. 2. 1. Physical selection methods. 
Physical selection involves the sequential enrichment of specific binding clones from a large excess 
of non-binding clones. In order to select the binding ligands against a specific protein using 
physical selection methods, the selector has to be used in a purified form and a significant quantity 
200-1000 ug is usually required.  
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There are two main types of these selection methods. In one, the selector is fixed to a solid support, 
such as polystyrene tube or pin and incubated with the library of polypeptides. After several rounds 
of wash steps those that bind to the selector can be eluted, while the unbound ones are washed 
away. In the second method the selector is labeled with biotin or fluorescein and selection is carried 
out using streptavidin coated magnetic beads (MACS) [344] in case of biotin and fluoresence-
activated cell sorting (FACS) [345] in case of fluorescein labelled selectors. Physical selection 
methods are used in in vitro and also in cell based display systems, where usually more than one 
round of selection is required.  
3. 2. 2. Genetic selection methods 
Physical selection methods are ideal for selecting binding ligands when a selector is available in a 
purified format in large quantity. Genetic selection methods allow to avoid the use of physical 
selection by using DNA encoding the gene of interest. One of the most widely used genetic 
selection method is the yeast two-hybrid (YTH) system [346], where each of the two interacting 
polypeptides is fused with one of the two functional subunits of a transcription factor. Interaction 
between the two polypeptides reconstitutes the transcription factor, enabling the transcription of a 
reporter gene, normally represented by the antibiotic resistance or a chromogenic enzyme. The 
problem with the system is that the polypeptide libraries may contain more than five billion clones 
which makes a primary selection round necessary before cloning to the yeast two-hybrid vector 
[347, 348]. Protein complementation assay (PCA) might serve as an alternative for the physical 
selection [349, 350]. In this method the enzyme required for cell survival, such as dihydrofolate 
reductase and β-lactamase, is divided into two fragments [350, 351]. The refolding of the reporter 
protein from its fragments is catalyzed by the binding of the supposed interacting proteins, and is 
detected as reconstitution of the enzymatic activity.
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3. 3. Phage Display 
Phage display has proven to be a powerful tool to display libraries containing millions of different 
peptides and proteins. In this method the coupling of phenotype and genotype is achieved through 
the specific properties of bacteriophages. The concept of displaying polypeptides on the surface of 
the filamentous M13 bacteriophage (phage) was introduced by Smith and colleagues in 1985 [352]. 
Smith demonstrated that phage genome could be manipulated by the insertion of a foreign DNA 
into a gene encoding phage coat protein without interfering with their infectivity.  
This way phages displaying proteins fused to their surface could be affinity purified against an 
immobilized specific immunoglobulin, thereby allowing over 1000 fold enrichment of correct 
phages from a background of phage particles not displaying the antigen. Depending on the 
application different types of phages can be used for phage display such as Lambda [353], T7 [354] 
and filamentous phage ( M13, f1, fd). By far the most popular phage that has been used for display 
is the non-lytic filamentous phage M13 [355, 356] (Figure 1.17). This type of phage infect only 
gram-negative bacteria and unlike lytic species such as Lambda and T7 replicate and assemble 
without killing the E. coli host [357]. The genome of M13 phage consists of a single stranded DNA 
molecule (6407 base pair long) encapsulated approximately 2700 copies of the major coat protein 
pVIII and with 5 copies of the four minor coat proteins (pIX, pVII, pVI, pIII) at distal end.  
 
Figure 1.17.  M13 bacteriophage structure. Coat proteins are indicated. ( Sulic. A. 2010. PhD thesis)
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During infection the minor coat protein pIII binds to the F-pilus of E. coli [358]. This protein 
consists of two N-termial domains (N1, N2) and one C-terminal domain (CT). The infection is 
mediated through the N2 domain and the F-pilus, which brings the TolA membrane protein of E. 
coli close proximity to N1 resulting in the interaction of the two. This process leads to the 
deposition of phage single stranded DNA into the cytoplasm and later converted into double 
stranded DNA by bacterial enzymes. The C-terminal domain is responsible for terminating phage 
assembly in the periplasm and the subsequent release from the cell membrane.  
In the phage display system pIII, pVIII and rarely pVI proteins are used. The DNA fragments of 
interest are cloned upstream of gene encoding pIII or pVIII, resulting in 3-5 recombinant proteins at 
one end of the phage int the case of pIII and 2700 copies of the original coat and recombinant 
proteins in the case of pVIII. The type of coat protein used as fusion partner should be considered, 
since pVIII is beneficial for the display of large number of smaller proteins, while pIII is more 
efficiently displays a fewer number of large proteins [356]. Excluding the display of short peptides 
pIII based systems are more commonly used.  
Phagemid vectors have been developed to overcome the difficulties working with phage genomes. 
The two basic type of polypeptide display is the polyvalent and the monovalent display. In 
polyvalent phage display the libraries are based on vectors derived from phage genome encoding all 
necessary proteins fro replication and assembly. Each copy of the coat protein displays the 
polypeptide, however the system is limited to smaller polypeptides since larger ones would interfere 
with the function of the coat proteins and eventually lead to the decrease in the infection property.  
Monovalent phage display the inserted DNA are cloned upstream the gene encoding coat protein 
pIII or pVIII and are presented in a single copy. This method has been used for cDNA libraries 
where the encoded protein domains are too large to be expressed on the coat protein without 
interfering with its function. In monovalent display the virion contains the phagemid carrying the 
antibiotic resistance marker, bacterial and phage origin of replication, the inserted DNA containing 
phage promoter upstream the gene encoding the coat protein and a packaging signal. The excess of 
wild type coat protein, necessary for phage replication, ssDNA production and assembly is provided 
by the helper phage, such as M13KO7 or VCS-M13, which has disabled packaging signal [359, 
360]. The infection with the helper phage initiates the assembly using phagemid DNA carrying the 
packaging signal and thus makes the phages functional.  
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Since the helper phage genome encodes wild-type coat proteins, typically 90% of phages display no 
recombinant protein at all and the vast majority that do display the fusion product will only contain 
a single copy. This way the recombinant proteins represent only a small portion of the total coat 
protein, allowing the phage overcoming the issues of polyvalent phage display. 
3. 3. 1. Phage antibody libraries 
Antibodies were the first proteins to be successfully displayed on the surface of the phage (d28), 
which was achieved by fusing the coding sequence of the antibody variable (V) regions encoding a 
single-chain  fragment variable (scFv) to the amino terminal of pIII minor coat protein of the phage. 
Since then, phage display has been efficiently used to generate antibody libraries and eventually 
isolate monoclonal antibodies from them. Phage antibody libraries can be divided into three type, 
namely: immune, naive and synthetic.  
Immune phage antibody libraries can be generated from the spleen B-cells of mice immunized 
with antigen [361] or from immune donors. The phage antibody repertoire will have antibodies 
enriched for a specific antigen and some of them will have been affinity maturated by the immune 
system [362]. This system provides antibodies with higher affinity and also higher quantity of 
antibodies might be obtained from the material originating form a single donor, which can be easily 
produced and manipulated. The construction of immune libraries have been reported from various 
species, including mouse [363, 364], human [365], chicken [366], rabbit [367], and camel [368]. 
The bottleneck of the system is that active immunization is not always possible due to ethical 
concerns, tolerance mechanisms and if toxic antigen is involved. Providing suitable sources of 
antibody producing B-cells or plasma cells, immune phage antibody libraries are ideal for analyzing 
autoimmune diseases [286, 369] or viral infections [370].   
Naive phage antibody libraries can be generated by harvesting the V-genes from the IgM mRNA 
of B-cells from unimmunized donors, isolated from peripheral blood lymphocytes [286], bone 
marrow or from animal sources [371].  
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V-genes are amplified from B-cells by family based oligonucleotides [372] where heavy and light 
chains are randomly combined and cloned to encode a combinatorial library of scFv or Fab 
antibody fragments. The affinity of the selected antibodies is proportional to the size of the library.  
This method gives access to antibodies which have not encountered the antigen yet. If sufficiently 
large and diverse naive libraries may be used to generate a large panel of antibodies against self, 
non-immunogenic or toxic antigens [373, 374]. 
Synthetic phage antibody libraries are built artificially, by in vitro assembly of V-gene segments 
and D/J segments. V-genes might be assembled by introducing a level of randomization to the CDR 
regions of germline V-gene segments [375] or rearranged V-genes [376]. The regions and the degree 
of diversity might be chosen in a way to correspond to t areas with the highest natural diversity of 
the antibody repertoire. Most of the natural structural diversity is found in the loop, most central to 
the CDR3 of the heavy chain, while the other five CDRs have less variation [377], therefore this has 
been the target for introducing diversity in synthetic libraries. 
Phage antibody selection involves the sequential enrichment of specific binding phage from a large 
excess of non-binding clones (Figure 1.18.). This is achieved by multiple rounds of binding to the 
target, washing to remove unbound clones and elution to retrieve specific binders for the target.  
Several different selections methods have been developed including panning on immobilized 
antigen coated onto solid support, selection using biotinilated antigen, affinity purification on 
columns and direct panning on cells. Phage antibodies bound to antigen can be separated from non 
specific clones by wash steps and positive clones can be subsequently eluted using several methods.  
These elution ways involve: acidic solutions such as HCl or glycine buffers, with chaotropic agents, 
with DTT by enzymatic cleavage or by competition with antibodies specific to the antigen. In a 
similar fashion what happens in vivo in the course of B-cell selection, phage antibodies with higher 
affinity might be enriched in successive rounds of selection by decreasing the quantity of antigen. 
This selection might be chosen to favor affinity or kinetic parameters such as off-rate, based on the 
use of limited and decreasing amounts of antigen and on performing the selection in solution rather 
than by using panning on coated antigen.  
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Figure 1.18. Phage  display  selection  cycle.  The isolation of a specific phage for it’s binding to a ligand 
leads to the isolation of the corresponding gene, while the unreactive clones are eliminated from the 
selection. Up to five rounds of selection can be performed, resulting in enrichment for phages that are 
represented in very low numbers in the original library. ( Sulic. A. 2010. PhD thesis) 
Antibodies selected from phage antibody libraries may be useful for analytic applications, however 
often need to be improved in terms of affinity to be used for therapeutic purposes or sensitive 
diagnosis. A possible solution for this problem is the in vitro affinity maturation of antibodies 
involving three steps: introducing diversity int he V-genes, selecting higher affinity variants and 
screening to discriminate between antibody variants regarding affinity or kinetics of binding. If the 
concern is not the affinity of individual antibodies but rather to generically increase effective 
affinities downstream methods can be applied. One system is to fuse genetically multimerization 
domains (e.g., jun/fos dimerization) [378] to the end of selected scFvs, which significantly 
improves sensitivity in ELISA and Western blot. Antibodies originating from phage display can be 
used for all application that use monoclonal antibodies, however they require an extra step to reveal 
them. This is usually achieved by the binding of a monoclonal antibody to the antibody-binding tag 
(e.g., myc) [379] or SV5 [286]. Some scFvs selected from phage antibody libraries have low yields 
and stability which can be improved when scFv genes are re-cloned into downstream vectors. These 
vectors might be for enhanced expression [380], mini antibodies, dimerization domains and Fabs 
[381], targeting intracellular immunization and enabling the transfer of V regions from scFvs to 
full-length immunoglobulins for mammalian expression [382].  
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3. 3. 2. Phage display for the study of celiac disease 
Phage display proved to be an effective tool to study the autoimmune response in Celiac disease 
[383-385]. This technique provides a tool to dissect the autoantibody response, select interacting 
proteins and also to identify specific antigens of the disease. In phage display of human Ab 
segments the patients antibody repertoire is fused to the coat protein of the phage vector carrying 
the encoded antibody gene [386], with each phage having a single Ab specificity.  
A system was developed in 2000 [387] for making large libraries exceeding the limits of traditional 
phage display technology. It is known that the affinity of the antibodies isolated from a library is 
proportional to the initial size of library used for selection [388, 389] and due to this large libraries 
have become essential sources of high-affinity antibodies [390, 391]. In the study first a relatively 
small primary library was created in a phagemid vector pDAN5 where VH and VL genes were 
separated by two non homologous lox sites. VH and VL genes of the primary library were 
recombined by infecting the phagemid to Cre expressing bacteria at high multiplicity of infection. 
The library created with this method was validated by selecting high affinity antibodies against 
various antigens. The same construct was used for production and analysis of six phage Ab libraries 
from the peripheral and intestinal lymphocytes of three CD patients [286]. VL chains were 
amplified using a set of oligonucleotides recognizing all human V genes, while oligonucleotides 
amplifying VH genes were specific to IgA [392]. VH and VL chains were cloned to the phagemid 
vector pDAN5 [387] to generate libraries to be studied.  
It was possible to isolate Abs to gliadin from all libraries while Abs to TG2 were only isolated 
intestinal lymphocytes libraries but not from those obtained from peripheral lymphocytes, revealing 
that humoral response against TG2 occurs at local level while against gliadin occurs both 
peripherally and centrally. Antibodies generated from the IBL of all three patients had a biased 
usage of the VH5 variable region family, which was supported in later studies [284, 294]. 
Selected ones of the isolated antibodies were cloned and expressed in scFv-Fc format [393] where 
the anti TG2 scFvs were genetically fused to human, mouse and rat Fc domains, allowing in vivo 
expression.  The  scFv-Fc  molecules  were  efficiently  secreted  as  homodimeric,  mimicking  the 
original structure of the antibody. The reactivity towards the target antigen TG2 was retained for all 
different constructs indicating that epitope recognition did not change due to expression as scFv-Fc. 
The in vivo expression in mice led to detectable serum levels even 40 days after the injection, with 
no immune response by the host. 
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Phage display is  effective tool  to  identify interacting proteins  to  a  specific target,  however  the 
presence  of  frame-shifted  DNA sequences  has  been  an  issue  of  the  system.  To  overcome this 
problem a method for the selection of DNA encoding open reading frames (ORFs) from non-coding 
DNA was developed [394] within the context of pPAO2 phagemid vector.  In this system DNA 
fragments were cloned in a fusion gene upstream of β-lactamase gene flanked by two homologous 
lox sites in frame with gene 3. Only phages that contained ORFs in frame with β-lactamase gene 
conferred ampicillin resistance and survived. After the selection of ORFs the lactamatase gene 
could be removed by Cre recombinase-induced recombination, allowing full display of in-frame 
ORF-g3p fusion products on phage surface. The pPAO2 vector based system was used to study the 
monoclonal antibody epitopes by filtered TG2 fragments [395]. Three monoclonal antibodies 
derived from the spleen cells of immunized mice were used for the selection of random fragments 
of TG2 gene expressed in pPAO2 phagemid vector. The epitopes recognized by the antibodies were 
determined by DNA sequencing, revealing that the epitopes overlap with each other and localized 
on the surface of TG2 protein. The phage display library of ORF fragments created from the mRNA 
of various tissues was used to study the interaction network of TG2 [396]. After two rounds of 
selection on TG2 the frequency of different ORFs in the page population was assayed by 454 
sequencing allowing the identification and ranking of several potential interactors. Several new 
interacting proteins were identified and it was also possible to determine the specific domains 
involved in the interaction for example for fibronectin. In a study made in 2013 sera from celiac 
patients were used to select immunoreactive antigens from cDNA phage-display library constructed 
from human tissues [397]. Clones encoding ORFs were selected using sere from celiac patients. 
Using multiple analysis provided by protein microarray 42 putative antigens were identified, 13 of 
which were confirmed to be specific for celiac sera.The majority of the identified clones encoded 
nuclear antigens and mostly involved in interaction networks with one another as well as with 
nucleic acids and carbohydrates. Several antigens identified have been implied to be involved in 
various diseases, however none have been described previously to be targets of autoimmune 
responses. The antibody response against these antigens was not abolished on a gluten free diet and 
was not shared with other autoimmune diseases, indicating that the response is CD specific and 
independent from gluten. The results of the study provided not only a deeper understanding of the 
autoantibody response in CD but also showed the potential of phage display technology for 
identifying new targets in autoimmunity research. 
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Chapter 4. Recombinant antibody technology 
4. 1. Early systems for therapeutic antibody generation 
Nowadays antibodies are used for several applications in research, diagnostics, and therapy. They 
are  widely  used  in  many  standard  assays  such  as  immunoblot,  flow  cytometry,  or 
immunohistochemistry. In addition this, the emerging field of proteome research has a huge need 
for binders against different protein antigens[398, 399]. Beyond this, recombinant antibodies are 
used for the diagnosis of different pathogens [400-402] or toxins [403, 404]. In the past decade, 
several  antibodies  have  been  developed  for  therapeutic  applications  [405],  primarily  targeting 
inflammatory  or  tumor  diseases  [406].  Polyclonal  antibodies  have  been  used  for  research  and 
diagnostics, however non-human polyclonal antibodies might exhibit immune response in humans 
interfering with therapeutic use for example after snake bites [407]. The first developed and most 
widely used technology for generation of monoclonal antibodies (mAbs) for therapeutic use was the 
hybridoma technology [408]. This technology was based on the fusion of antibody producing spleen 
cell from immunized mice or rats with immortal myeloma cell lines. The bottleneck of the system is 
that mice immunization cannot be used for highly toxic or conserved antigens. Another issue is the 
high immunogenicity of these foreign proteins in humans as well as the weak interaction that mouse 
antibodies  typically  have  with  human  complement  and  FcγRs,  resulting  in  inefficient  effector 
functions.  In  addition,  mouse  antibodies  do  not  bind  the  human  salvage  receptor  FcRn  [409] 
resulting in a terminal half-life that is typically less than 20 hours [410, 411]. These limitations of 
mouse antibodies  have largely  been overcome by their  chimerization or  humanization.  A great 
success  in  antibody engineering was  the  possibility  to  generate  chimeric  antibodies,  where  the 
binding activity of  IgG molecules is  generated by the variable domains of the heavy and light 
chains. As antibodies are well conserved through evolution, it was possible to create chimeras by 
fusing murine variable domains, responsible for the binding activity, with human constant domains 
[412]  leading  to  the  development  of  a  new generation  of  therapeutic  candidates  [413].  These 
chimeric antibodies were 70% human and possessed a fully human Fc portion, which made them 
considerably less immunogenic in humans allowing them to interact with human effector cells and 
the complement cascade. 
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The development of antibody engineering techniques it has made it feasible to decrease further the 
murine part of the generated mAbs by replacing the hypervariable loops of a fully human antibody 
with  the  hypervariable  loops  of  the  murine  antibody  of  interest,  using  an  approach  called 
complementarity-determining  region  grafting  [414].  This  resulted  in  the  generation  of  the  first 
humanized antibodies which were 85–90% human and are even less immunogenic than chimeric 
antibodies. Most of the approved mAbs in current use are either chimeric or humanized. Another 
major improvement came with the development of in vitro selection methods, the most successful 
one being phage display which was discussed in the previous chapter. With the ever increasing 
power of antibody engineering, it became possible to clone entire repertoires of antibody fragment 
genes, from immunized or non-immunized animals or humans.
4. 2. Recombinant antibody formats
New  antibody  generation  technologies  have  increased  the  amount  of  antibodies  for  different 
applications and, therefore, also the need of efficient production systems. IgG is a heterotetrameric 
molecule consisting of two heavy and two light chains connected and stabilized by disulfide bonds 
[415].  Because  of  this,  IgG  molecules  require  correct  folding  apparatus  and  an  oxidizing 
environment for the generation of disulfide bonds. Since many traditional expression hosts do not 
provide  these  mechanisms,  for  efficient  production,  smaller  antibody  fragments  have  been 
developed which combine easier production with full antigen binding capacity of an IgG (Figure 
1.19). In addition, the development of smaller fragments was the basis for most of the in vitro 
antibody generation systems [416-419].  These antibody fragments can be used for applications, 
where epitope binding is sufficient for the desired effect including therapeutic applications such as 
virus neutralization or receptor blocking.                                                                                                  
4. 2. 1. Single domain antibodies
The  smallest  antigen  binding  fragment  of  immunoglobulins  maintaining  its  complete  antigen 
binding site is the Fv fragment, which consists only of variable (V) regions (Figure 1.19). In 1989, 
it  was demonstrated that  mouse variable  domains could be used as  single  binding units  [420], 
however the vast majority of these domains aggregate spontaneously. 
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Later it was found that camelids and sharks express a type of antibodies devoid of light chains [421] 
and new antigen receptor antibodies (IgNAR) [422]. These antibodies have a single variable domain 
(called VHH for camelids and V-NAR for sharks), which generates high affinities towards a large 
spectrum of antigens. These small domains (13 kDa) can be easily produced in bacteria or yeast and 
called domain antibodies (dAbs), single-domain antibodies (sdAbs) or nanobodies. 
Figure 1.19. Recombinant antibody formats for different applications compared to IgG. Red and dark red: 
variable  regions;  blue:  constant  regions;  green:  artificial  peptide  linkers.yellow:  dHLX  represents 
amphiphatic helices used for dimerization of scFv fragments. [423]
4. 2. 2. Multi domain antibodies
The scFv fragments are composed of the variable domains of heavy and light chain connected by a 
flexible linker peptide (Figure1.19). These molecules were described as small fragments capable of 
retaining the binding activity of the full IgG molecule in a monovalent fashion. Fab fragments are 
composed of  one  constant  and one variable  domain of  each of  the  heavy and the  light  chain, 
connected also by a flexible linker peptide (Figure 1.19.). 
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Nowadays scFvs and Fabs are the most widely used antibody fragments produced in prokaryotes. 
The issue of scFvs and Fabs is the very short half-life in serum (~2 h). By decreasing the length of 
the linker between the two domains, a dimer format was introduced called diabody [424] (Figure 
1.19).  Diabodies  are  compact,  medium-size  (60 kDa)  molecules  and can be a  good choice  for 
imaging  purposes  or  radioimmunotherapy.  Besides  increasing  the  molecular  weight,  the 
dimerization  provides  bivalency,  which  leads  to  a  higher  avidity  and  higher  tumor  retention. 
Because of these features diabodies provide rapid tissue penetration, high target retention and rapid 
blood clearance. Because of the fact that they are rapidly eliminated through the kidneys, they limit 
the exposure to the bone marrow, which is most often the dose-limiting organ with intact radio-
labelled mAbs. Other antibody formats have been produced in prokaryotic and eukaryotic cells, for 
example,  disulfide-bond  stabilized  scFv  (ds-scFv)  [425],  single  chain  Fab  fragments  (scFab) 
combining scFv and Fab properties [426] (Figure 1.19.).  
For most therapeutic applications, the Fc moiety of an immunoglobulin is essential for the method 
of  action  as  it  mediates  the  effector  functions  such  as  cellular  dependent  cytotoxicity  or  the 
activation of the complement system. Therefore,  antibody fragments have been fused to the Fc 
domain to regain effector functions and avidity [427, 428]. These constructs include scFv-Fc where 
the scFv fragment is substituted of Fc domain composed of CH2 and CH3 domain (Figure 1.19.) 
and minibody where scFv fragments are connected with CH3 domain (Figure 1.19.).  The main 
importance of the Fc portion is that hey can recruit the complement cascade through interaction 
with C1q, ultimately leading to the formation of pores in the targeted cell membrane, or they can 
recruit effector cells through interaction with the C4b/C2b/C3b complex bound to the target cell 
surface and the receptor CR1 (complement receptor). Another important mechanisms by which IgG 
antibodies  activate  the  cellular  immune  system  is  via  interaction  of  the  Fc  domain  with  Fcg 
receptors  (FcgRs).  The  human  FcgR family  contains  six  known  members  in  three  subgroups, 
including FcgRI (CD64), FcgRIIa,b,c (CD32a,b,c) and FcgRIIIa,b (CD16a,b), expressed by various 
effector cells of the immune system, including macrophages, neutrophils, dendritic cells and natural 
killer (NK) cells. NK cells are the main agent of antibody-dependent, cell-mediated cytotoxicity 
(ADCC). These cells can be recruited and activated through the interaction between FcgRIIIa and 
the  Fc  region,  leading  to  the  formation  of  an  immunological  synapse,  the  release  of  perforin/ 
granzyme and the establishment of the Fas/FasL interaction, both leading to apoptosis of the target 
cells. 
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4. 3. Recombinant antibody expression
Recombinant antibodies can be produced in large quantity and good quality in several different 
hosts. Prokaryotic hosts include Gram-negative bacteria such as Escherichia coli and also Gram-
positive bacteria as Bacillus brevis [429] Bacillus subtilis [430] and Bacillus megaterium [431]. The 
most  important  eukaryotic  hosts  are  mammalian  cells,  however  antibodies  can  be  efficiently 
produced in yeast such as Pichia pastoris [432], filamentus fungi as Trichoderma and Aspergillus 
species [433] or insect cells like Spodoptera frugiperda, or Drosophila melanogaster [434]. In this 
chapter prokaryotic production of recombinant antibodies will be described through Escherichia 
coli host. For eukaryotic expression mammalian hosts will be studied in more detail.
4. 3. 1. Prokaryotic expression system
Escherichia  coli  is  the  most  important  prokaryotic  production system for  recombinant  proteins 
[435, 436]. For production of functional antibody fragments, the key feature is the secretion of both 
V chains into the periplasmic space of E. coli where the oxidizing environment allows the correct 
formation of disulfide bonds and the assembly to a functional Fv fragment [437]. This strategy was 
the first one allowing the expression of functional Fab fragments in E. coli described in 1988 [438]. 
The production of recombinant antibodies in the reducing cytoplasmic compartment results mostly 
in  non-functional  aggregates  [439]  and  recovery  of  functional  antibody  fragments  from  cyto-
plasmic  inclusion  bodies  by  complete  denaturation  and  refolding  [440]  is  often  not  efficient. 
Nowadays most  antibody fragments  are  produced in  the periplasm of  E. coli  using N-terminal 
leader sequences targeting the periplasmic Sec pathway [441], for example signal peptides derived 
from outer membrane protein A (OmpA), alkaline phosphatase A (PhoA), or pectate lyase B (PelB) 
[442,  443].  After  expression,  recombinant  antibodies  are  usually  isolated  from the  periplasmic 
fraction  [444,  445]  but  also  from  the  culture  supernatant  [446].  Expression  of  recombinant 
antibodies can also be increased by optimization of cultivation parameters, such as temperature, 
media, or additives which depend on the individual antibody fragment [447, 448]. The production 
system itself influences the production rate. Very high yields of antibody fragments produced in E. 
coli are mainly provided by high-cell density fermentation in bioreactors [449] or optimized shake 
flasks [450].
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5. 3. 2. Eukaryotic expression in mammalian cells
Today, 95% of the currently approved therapeutic antibodies are still produced in mammalian cell 
lines  despite  relatively  high  production  costs  and  difficult  in  handling.  This  is  because  of  the 
advanced mammalian folding, secretion and post-translational apparatus is capable of producing 
antibodies indistinguishable from those in the human body with least concerns for immunogenic 
modifications. The system is also capable of highly efficient secretion of large and complex IgGs 
and in combination with the folding and post-translational control it results in high product quality. 
Chinese  hamster  ovary  (CHO)  cells  are  the  most  common  cells  applied  in  the  commercial 
production of recombinant antibodies. This cell line isolated in the 1950s gave rise to a range of 
genetically different progeny, such as K1-, DukX B11-, DG44- cell lines and others which differ in 
protein product quality and achievable yield. In addition, Per.C6 cells, mouse myeloma NS0 cells, 
baby hamster kidney (BHK) cells and the human embryonic kidney cell line HEK293 has proved to 
be efficient production hosts. In order to have an effective production the antibody gene expression 
cassettes  have  to  be  stably  integrated  into  the  host  cell  genome.  Strong  promoters  like  the 
immediate early cytomegalovirus (CMV) or the cellular elongation factor (EF) 1-alpha promoter 
and polyadenylation sites from the simian virus (SV) 40 or the bovine growth hormone (BGH) for 
improved mRNA stability and translation efficiency are usually implemented into the expression 
vector. The generation of high producer cell lines has been dramatically improved and accelerated 
[451], however it is still too expensive, time-consuming and laborious for research applications, or 
if  large  numbers  of  individual  antibodies  have  to  be  produced.  Transient  and  semi-stable 
mammalian antibody expression is  much more suitable  in  many cases  since  it  allows fast  and 
parallelized production without any need to generate producer cell lines [452]. Transient antibody 
production is suitable for small-scale production in antibody screening [453], but also capable to 
generate grams of antibodies [454, 455]. 
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RESULTS 
Chapter 1. Developing TG2 inhibitor antibody 
Recombinant antibody technology provides an effective tool for generating therapeutic antibodies 
for a great variety of diseases including cancer and autoimmune diseases. Celiac disease is among 
the most widespread of the autoimmune diseases affecting the 1% of western population. Despite 
the efforts no effective therapeutic has been generated for the disease, therefore the only known 
treatment is lifelong gluten free diet. Based on this there is an increasing need to generate 
recombinant antibodies with the ability to inhibit the enzymatic function of TG2 and this way 
contribute to the treatment of the disease.  
The main objective of our project is to dissect the autoantibody response in CD. One feature of the 
antibodies that we would like to determine is the inhibitory effect on TG2 enzymatic activity. To 
achieve this goal we had to develop a system to efficiently test TG2 in vitro transamidating activity 
and also a reliable inhibitor antibody that we could use as control in the experiments. In 2013 a 
patent has described the generation of a series of TG2 inhibitory antibodies (ref:WO2013/175229 
A1). Antibodies were created by immunizing mice with recombinant human TG2 encompassing 
amino acids 143-473 of the TG2 core. The sequence of the best TG2 inhibitor was retrieved and 
used to generate the antibody in scFv-Fc format, widely used in our systems. The purified antibody 
was tested for its specificity and used to develop the inhibition assay on TG2. 
Workflow:
• Construction of antibody in scFv-Fc format in pMA-T vector
• Cloning and expression in pMB-SV5 vector.  
• Developing TG2 inhibition assay on solid surface and in solution 
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1. 1. Construction of antibody in scFv-Fc format in pMA-T vector
In  order  to  generate  a  control  inhibitory  antibody  we  used  the  sequence  of  the  best  inhibitor 
described  in  the  patent  (ref:WO2013/175229 A1) (Table 2.1). The antibody with code hAb004 
comprised of variable heavy chain IGHV3-23*01 F and variable light chain IGKV1-16*01 F. The 
antibody was designed by GENEART synthesis in scFv format into pMA-T conventional plasmid. 
In the construct the variable chains were cloned in an order VL followed by VH and the two chains 
were separated by a flexible loxP511 protein linker to form the functional scFv. At the N-terminal of 
the VL a BssHII restriction site, while at the C-terminal of the VH an NheI site was introduced for 
the efficient subcloning into pMB-SV5 vector.  
 
Table 2.1. The sequence and VH/VL usage of hAb004 anti TG2 antibody was determined. 
1. 2. Cloning and expression in pMB-SV5 vector.  
In order to express the antibody in the scFv-Fc format widely used in our systems hAb004 was 
subcloned  into  pMB-SV5  vector  (Figure  2.1).  The sub-cloning was characterized by the use of 
BssHII-NheI cassette. For the mammalian expression a CMV promoter and a leader sequence was 
introduced at the N-terminus. At the C-terminus the CH2 and CH3 domains of Fc from Human 
IgG1 were connected to the scFv fragment by a Hinge region. An SV5 tag at the 3’ of the construct 
was present for uniform detection.  
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Figure 2.1. Schematic representation of the cloning vector (A) modified from[393] and expressed scFv-Fc 
(B). 
After cloning vector was checked by DNA sequencing and the purified plasmidic DNA was 
transfected into CHO-S cells. The secretion of the scFv-Fc in the culture medium was analyzed 
after 72 h by ELISA on plates coated with hTG2, mTG2 and unrelated control protein (BSA). The 
results were determined by recognition of the SV5 tag at the C-terminus of the construct. hAb004 
had reactivity on hTG2 with no cross-reactivity with the murine protein, as it was reported in the 
patent (ref:WO2013/175229 A1) (Figure 2.2). 
Figure 2. 2. TG2 inhibitory antibody hAb004 expressed in CHO cells was tested as primary antibody in 
ELISA on hTG2/mTG2/BSA. As C(+) an scFv-Fc with murine cross-reactivity was used. As C(-) a non TG2 
specific antibody was used. 
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Stable cell line was made by growing cells in the selective agent for the Hygromycin resistance. 
Purification of the scFv-Fc hAb004 was done using Protein A agarose with a production yield 
ranging 3 mg/l of culture. Purified hAb004 analyzed by Comassie and Western blot under reducing 
conditions (Figure 2.3.). The antibody was revealed by a mouse antibody recognizing the SV5 tag, 
which was followed by anti Mouse-AP secondary antibody. Purified hAb004 appeared at predicted 
molecular weight which was around 55 kDa due to the fusion of the scFv with constant domains 
and SV5 tag and additionally the loss of interchain disulfide bond in the Hinge region as result of 
the reducing condition.  
Figure 2.3. Comassie staining (A), and Western blot (B) image of purified hAb004 antibody in scFv-Fc 
format.
The specificity of purified hAb004 was dissected by ELISA made on hTG2 and mTG2 (Figure 
2.4.). The antibody was used in different concentrations (0,1-0,25-0,5 ug/ml) to further investigated 
the reactivity. As is has been seen before hAb004 had specific reactivity towards hTG2.
               Figure 2.4. ELISA on hTG2 and mTG2 using three dilutions of hAb004: 0.1-0.25-0.5ug/ml.
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1. 3. Developing TG2 inhibition assay on solid surface and in solution
In order to develop an inhibition assay first an ELISA test measuring TG2 in vitro transamidating 
activity was done. The test was based on the coupling of 5 - (biotinamido)-pentyalamine to NN-
dimethylcasein which was catalyzed by recombinant hTG2. The biotinilated primary amine and 
DMC were incubated for 1 hour at 370C in the presence of TG2, DTT and Ca2+. The incorporation 
of biotin into NN-dimethylcasein was revealed by Streptavidin conjugated with peroxidase. The 
inhibitory effect of hAb004 was investigated by introducing a preliminary incubation step of TG2 
and the antibody. This step allows the antibody to bind TG2 molecule and inhibit it’s enzymatic 
activity before that could meet its substrates. In the case of inhibition TG2 transamidating activity is 
blocked causing a significant decrease in the signal (Figure 2.5).  
 
Figure 2.5 Schematic representation of in vitro assays. DMC indicated in brown, 5’-
Streptavidin(biotinamido)-pentyalamine in dark green stick while Streptavidin conjugated peroxidase with 
an X. A. In vitro transamidation assay where the coupling of biotinilated primary amine and DMC is 
catalyzed by recombinant hTG2. B. In vitro inhibition assay where the scFv-Fc hAb004 is blocking the 
enzymatic effect of hTG2 molecule, interfering with the coupling of the two substrates. 
In the inhibition assay hAb004 was used in different concentration ranging from 24nM-0,188nM 
(Figure 2.6). As negative control for inhibition a non TG2 specific antibody was used in the same 
scFv-Fc format. In the experiment hAb004 proved to have a significant inhibitory effect on TG2 
enzymatic activity in a dose dependent manner. The inhibitory effect was similar what was seen in 
the patent (ref:WO2013/175229 A1) meaning that hAb004 retained its inhibitory potency in scFv-
Fc format.  
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Figure 2.6 In vitro transamidation assay performed on solid surface using hAb004 in concentrations ranging 
from 24-0,188nM. 
Antibody  hAb004 was tested for the inhibitory effect in solution. In the assay TG2 and hAb004 
were pre-incubated to allow the antibody to bind and inhibit TG2. After incubation the mix was 
substituted with 5’- (biotinamido)-pentyalamine and N N-dimethylcasein. A volume of the mix 
which corresponded to 0,5ug of DMC was separated by SDS/PAGE and transferred onto 
nitrocellulose membrane. Incubation was done with Streptavidin-Alkaline Phosphatase antibody 
and revealed by NBT/BCIP. As control positive for  transamidation TG2 used in the presence of 
Ca2+ without a pre-incubation step with the antibody, while negative control was TG2 with no Ca2+ 
added. Control negative antibody was a non TG2 specific antibody in same scFv-Fc format. The 
reduction in the signal closely mirrors the ratio of antibody added to the reaction. The inhibitory 
effect is corresponding what we saw in ELISA experiments (Figure 2.7.). 
Figure 2.7. In vitro transamidation assay in solution. C(+) is hTG2 used in the presence of Ca2+ while C(-) is 
hTG2 with no activating Ca2+ added. C(-) antibody was a non TG2 specific antibody in scFv-Fc format. 
hAb004 was used in different concentrations ranging from 1.5-24nM.
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Chapter 2. Dissecting anti TG2 antibody response in CD 
by phage display technology 
 Aim of the research 
Celiac disease (CD) is characterized by destruction of intestinal epithelium and the secretion of 
gluten-and TG2-specific IgA and IgG antibodies. TG2 acts not only as the main trigger of the 
disease but also as a self antigen and therefore the study of autoimmune response against this 
enzyme is crucial for understanding the disease. The aim of the research is to dissect the molecular 
basis underlying the biological properties of TG2 via the characterization of autoantibody 
specificities to TG2 epitopes in celiac disease. Antibodies in scFv format were derived from phage 
antibody libraries originating from the intestinal biopsy lymphocytes of CD patients. These 
antibodies were clustered into epitope groups according to their cross-reactivity with murine TG2 
and by competing them with reference antibodies representing different VH families. All together 
four epitope clusters were determined, and one antibody representing each epitope cluster was 
further characterized in scFv-Fc format expressed in eukaryotic cells. The interaction between 
antibody and TG2 in the extracellular environment was analyzed by staining TG2 expressed on cell 
surface (csTG2) and TG2 bound to fibronectin (FN). All but one epitope groups were able to stain 
csTG2 indicating that most epitopes are displayed on the surface of cells. VH5 antibodies 
representing the most dominant antibody gene family in CD were not able to stain FN-bound TG2 
suggesting that this epitope is overlapping with FN binding site on TG2 molecule. The inhibitory 
effect of antibodies on TG2 enzymatic activity was tested by in vitro transamidating assay, where 
only one epitope group had inhibitory effect on the activity of the enzyme. 
Workflow:
• Construction of phage antibody libraries
• Characterizing antigen specificity in scFv format 
• Clustering antibodies into epitope groups in scFv format 
• Cloning and expression in scFv-Fc format 
• Dissecting TG2-autoantibody interaction in the extracellular environment 
• Investigating inhibitory effect of antibodies in scFv-Fc format 
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2. 1. Introduction to the results 
The aim of the project was to dissect the autoantibody response against the self antigen TG2 in the 
onset of Celiac disease. In the course of the project we used a combination of molecular biological 
tools that enabled a deeper understanding of the response (Figure 2.8).  
(  
 Figure 2.8. Schematic representation of workflow used to dissect autoantibody response against TG2.
A. Construction of phage antibody libraries: Phage antibody library generated from the intestinal 
biopsy lymphocytes of 7 CD patients, where the antibody repertoire in scFv format was displayed 
on filamentous phage.  
B. Characterizing antigen specificity in scFv format: Antibodies coming from phage antibody 
libraries were tested for their reactivity and specificity. The selection output of the six libraries were 
first screened on hTG2 by ELISA. The clones found to be positive were tested for their specificity 
using mTG2 in ELISA experiments.  
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C. Clustering antibodies into epitope groups in scFv format: Antibodies in scFv format were 
clustered into epitope groups by competing them with reference antibodies. The experiment was 
performed as competition phage ELISA where reference antibodies in scFv-Fc format, representing 
different VH families were used to compete the positive clones of phage antibody libraries 
expressed in scFv format.  
D. Cloning and expression in scFv-Fc format: Reference clones representing each epitope cluster 
were cloned into mammalian expression pMB-SV5 vector and expressed in scFv-Fc format in 
Chinese hamster ovary (CHO) cells. Antibodies were tested for retaining reactivity in scFv-Fc 
format by performing ELISA on different TG2 proteins. 
E. Dissecting TG2-autoantibody interaction in the extracellular environment: The effect of 
TG2-FN interaction on antibody recognition was investigated. Competition ELISA was performed 
using FN 45kDa domain to compete antibodies for binding TG2.  
Antibodies were tested to recognize cell surface TG2 by using them for staining various TG2 
expressing cell lines. 
F. Investigating inhibitory effect of antibodies in scFv-Fc format: The inhibitory properties of 
antibodies was determined by using them in vitro transamidation assays performed in solution and 
in solid surface. 
2. 2. Construction of phage antibody libraries 
Phage display of human antibody fragments proved to be an extraordinary tool to study the 
autoantibody response in celiac disease. In this method the patients antibody repertoire is expressed 
fused to the coat protein of a filamentous phage carrying the encoded antibody gene. In the system 
each phage carries a single antibody specificity allowing to dissect the antibody response against 
self antigen TG2.  
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Phage antibody libraries used in this study were constructed as described in Marzari et al. [286] 
where libraries were generated from the IBL of three untreated adult CD patients. The biopsy 
materials were obtained from patients undergoing intestinal biopsy in order to confirm the 
diagnoses. Total mRNA preparation of IBL was performed and followed by cDNA synthesis using 
random primer reverse transcription and normalization. The VH and VL chains were amplified from 
cDNA by PCR using a set of oligonucleotides that recognize human V genes [392]. The 3’ primer 
used for the VH chain was specific for IgA antibodies, the most abundant ones in the anti TG2 
response. Amplified VH and VL chains were assembled by PCR [380] and cloned in scFv format 
into pDAN5 phagemid vector [387] (Figure 2.2). In the vector variable chains are cloned in an order 
VL followed by VH and the two chains are separated by loxP511 protein linker to form the 
functional scFv (Figure 2.9). The scFv genes are cloned upstream the gene encoding pIII minor coat 
protein allowing the antibody expression fused to the phage surface. Antibodies were affinity 
selected on hTG2 and after every cycle of selection the eluted phages were re-amplified for the next 
cycle and tested by ELISA against hTG2.  
 
Figure 2.9. (A,) Map of phagemid vector pDAN5 with an scFv cloned [387]. (B,) Structural image of scFv. 
The VL and VH chains are separated by the loxP511 flexible linker peptide. 
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2. 3. Characterizing antigen specificity in scFv format 
The selection output of phage antibody libraries generated from the IBL of seven patients was 
analyzed for the positivity on the selecting antigen by screening in phage ELISA on hTG2. A 
number of 28 clones proved to be hTG2 positive. The positive clones were tested for their 
specificity first, by testing reactivity on recombinant TG2 with human and mouse origin (Figure 
2.10.).  
Figure 2.10. Reactivity of the 28 positive clones of the selection output examined by phage ELISA. (A,) 14 
clones proved to be hTG2 specific. B. Total number of 14 clones showed cross-reactivity with mTG2. 
It is known that there is a significant homology between the human and mouse TG2 and due to this 
phage ELISA experiments were performed using these proteins and an unrelated control (BSA). As 
it was expected a significant portion of the clones had cross-reactivity. Out of the 28 hTG2 positive 
clones 14 showed cross-reactivity with mTG2 while 14 clones proved to hTG2 specific. This ratio 
of the clones correlates what has been shown in other studies [286, 294]. 
2. 4. Clustering antibodies into epitope groups in scFv format 
Anti TG2 antibodies have been reported to recognize distinct epitopes located on TG2 molecule 
[286, 294]. In order to investigate the epitope usage of the 28 selected clones competition phage 
ELISA experiments were carried out using reference antibodies. The reference antibodies used for 
the test were coming from the phage antibody library described in a previous paper by our group 
[286] were expressed in scFv-Fc format [393], by the genetic fusion of anti TG2 scFv to human 
IgG1 Fc domain. Three reference antibodies represented two epitope groups [286]. Two VH5 
antibodies in scFv-Fc format (2.8 and 4.1) [393] used as reference antibodies for competing clones 
with mTG2 cross-reactivity belonged to Epitope 1 [286] (Figure 2.11).  
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All VH5 antibodies from CD patients were shown to recognize this epitope which was shared by 
murine TG2. From the 14 tested mTG2 reactive clones 11 had competition with reference antibody 
2.8 and 9 with reference antibody 4.1. As most of the tested clones had high competition with both 
VH5 antibodies we can consider Epitope 1. as the reference epitope for clones having cross-
reactivity with the murine protein. 
Figure 2.11. Competition pattern of mTG2 cross-reactive clones on VH5 reference antibodies. (A) 
Competition result using reference antibody 2.8 (B) Competition result using reference antibody 
4.1 .Antibodies considered to represent Epitope 1. indicated in green. 
Antibodies specific for hTG2 were tested with a VH3, Epitope 2. antibody (4.2) [456] in scFv-Fc 
format (Figure 2.12.). Antibodies belonging to this cluster were directed to a second, less well-
defined epitope, characterized by an exclusive presence on hTG2, in spite of the high homology 
between hTG2 and murine TG2. From the 11 tested clones 4 had significant competition with the 
reference antibody while 7 had no competition indicating that there are at least two epitope clusters 
among the TG2 specific clones. The antibodies having competition with the reference antibody 
represented Epitope 2. while those which were not competing represented Epitope 3. cluster. The 
last competition study was carried out using reference antibody 4 (7.12), a VH3 antibody which has 
been shown to have different epitope recognition than the ones used previously (Figure 2.12.). 
Competition experiment was carried out using two Epitope 1. antibody (2.8, 6.17) one Epitope 2. 
(4.2) and two Epitope 3. antibody (7.27 and 3.7). Only one antibody, 7.27 had competition with 
reference antibody 4. and became representative of Epitope 4. 
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Figure 2.12. Competition pattern of TG2 specific clones on hTG2 specific clones. Clones competing with 
Reference antibody 3. clustered into Epitope 2. (indicated in red) while clones not competing clustered to 
Epitope 3 (indicated in violet). Reference antibody 4. competed only with one antibody which represented 
Epitope 4. (indicated in yellow). 
The results of the competition experiments indicate that there are at least four epitope groups among 
the TG2 positive clones (Figure 2.13). Epitope 1., found to be the largest, contained all the clones 
showing mouse cross-reactivity and competition with two VH5 antibodies. The clones specific to 
hTG2 were tested with two VH3 antibodies and divided into three clusters. The findings are 
supported by data from the literature [294] where similar conclusions were made on mAbs 
generated from single plasma cells of CD patients. 
Figure 2.13. Grouping of TG2-reactive scFvs according to epitope binding.  
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2. 5. Cloning and expression in scFv-Fc format 
In order to further investigate the autoantibody response against TG2 five clones representing all the 
four epitope clusters were selected to be cloned and expressed in scFv-Fc format (Table 2.2.). Two 
antibodies (2.8, 6.17) representing Epitope 1. belonged to VH5, the most abundant antibody gene 
family of the epitope cluster. The antibody representing Epitope 2. (4.2) belonged to VH3, the 
antibody representing Epitope 3. (3.7) belonged to VH1 and the Epitope 4. antibody (7.27) 
belonged to VH3 antibody gene family.  
Table 2.2. The VH and VL genes usage of the reference antibodies representing all the four epitope cluster.
For the expression in scFv-Fc format reference scFvs from pDAN5 phagemid vector were cloned to 
modified pMB-SV5 mammalian expression vector [393]. As described before, the subcloning was 
characterized by the use of BssHII-NheI cassette. After cloning all vectors were analyzed by DNA 
sequencing and transfected into CHO cells. The secretion of the scFv-Fcs in the culture medium 
was analyzed after 72 h by ELISA on plates coated with hTG2, mTG2 and unrelated control protein 
(BSA). The results were determined by recognition of the SV5 tag at the C-terminus of the 
construct. All antibodies were expressed and had the same reactivity as in scFv format (Figure 
2.14).  
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Figure 2.14. ELISA of supernatants of cultured CHO-s cells transfected with plasmid pCDNA3.1/Hygro(+) 
carrying scFvs fused to Fc domain of human IgG1.
Stable cell lines for each clone were made by growing cells in the selective agent for the 
Hygromycin resistance. Purification of the scFv-Fcs was done using Protein A agarose with a 
production yield ranging 4-7 mg/l of culture. Purified scFv-Fcs were analyzed by Comassie and 
Western blot under reducing conditions (Figure 2.15.). Antibodies were revealed by a mouse 
antibody recognizing the SV5 tag, which was followed by anti Mouse-AP secondary antibody. 
Antibodies appeared at predicted molecular weight which was around  55 kDa.  
 
Figure 2.15. Comassie staining (A) and Western blot (B) of purified scFv-Fcs under reducing condition. 
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The specificity of purified scFv-Fcs was dissected by ELISA made on hTG2, mTG2 and an 
unrelated control protein (BSA) (Figure 2.16). Antibodies were used in different concentrations 
(0,1-0,25-0,5 ug/ml) to further investigated the reactivity. Specificity was retained for all antibodies 
in scFv-Fc format giving us two distinct groups. The Epitope 1. antibodies recognized both hTG2 
and mTG2 in a concentration dependent manner. This correlates to the reactivity what they had as 
phage expressed scFvs and also what is typical for anti TG2 antibodies belonging toVH5 antibody 
gene family. The other three epitope groups also kept their specificity towards hTG2. 
Figure 2.16. Saturation binding curves for selected scFv-Fcs representing two distinct groups. Antibodies 
used in increasing concentrations from 0,1-0,5 ug/ml. A. Epitope 1. antibodies having cross-reactivity with 
mTG2. B. Three antibodies representing Epitope 2, 3, 4 being specific to hTG2. 
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2. 6. Dissecting TG2-autoantibody interaction in ECM 
2. 6. 1. Analyzing the effect of TG2-FN interaction on antibody binding.
In the extracellular environment TG2 interacts with the ubiquitous and abundant ECM protein 
fibronectin (FN) [85]. The specific binding between TG2 and fibronectin in the ECM involves the 
gelatin-binding domain of fibronectin [86] and the N-terminal β-sandwich domain of TG2. The 
formation of TG2-fibronectin complex has a significant impact on cell adhesion and migration 
signaling events [457]. The effect of TG2-fibronectin association on antibody binding has been 
reported by a study using monoclonal antibodies isolated from single plasma cells of CD patient 
[294]. To investigate if the association with fibronectin influences the binding between TG2 and Ab, 
we tested the ability of scFv-Fcs from each epitope group to react with fibronectin-bound TG2 
(Figure 2.17). We found that scFv-Fcs representing Epitope 1. lost their reactivity when TG2 was 
associated with fibronectin. This indicates that this epitope overlaps with the fibronectin binding 
site in TG2. The other scFv-Fcs representing the other three epitope groups did not loose their 
reactivity suggesting that their epitopes are located in a different position in TG2 molecule. 
Figure 2.17. Comparison of scFv reactivity to TG2 alone and TG2 captured on human fibronectin. 
Antibodies in scFv-Fc format used in increasing concentrations ranging from 0,1-0,5ug/ml. A. Epitope 1. 
antibodies loosing their reactivity when TG2 is associated with fibronectin. B. Epitope 2., 3., and 4. 
antibodies have no difference in signal intensity when TG2 was bound to fibronectin. 
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2. 6. 2. Investigate the staining properties of antibodies on csTG2 
TG2 has been found to be expressed on the surface of different cell types, where it interacts with 
fibronectin, integrins of the β1 and β3 subunit and heparan sulfate proteoglycans [85, 90, 105]. Anti 
TG2 antibodies isolated from single plasma cells of CD patients expressed in IgG1 format were 
tested for staining csTG2 on the surface of dendritic cells [294]. None of the antibodies showed 
staining on csTG2. We wanted to investigate if different origin and expression can have an effect on 
staining properties, since our antibodies are originating from phage antibody libraries and expressed 
in scFv-Fc format. It is possible to detect TG2 on the surface of various cancerous cell lines with 
mAb TG100. We used this antibody as a control to test the staining properties of our antibodies in 
flow cytometry using high TG2 expressing ovarian cancer cell lines such as SKOV3 and MCF7 
(Figure 2.18). All except one epitope group (Epitope 4.) representatives were able to stain csTG2. 
This indicates that most of the epitopes are accessible when TG2 is expressed on cell surface. Both 
VH5 antibodies belonging to Epitope 1. were able to stain csTG2. Considering the biased usage of 
this VH family in CD we may conclude that the great majority of anti TG2 antibodies can bind to 
TG2 expressed on cell surface in the course of the disease.
Figure 2.18. Reactivity of Abs with csTG2. Representative flow cytometry histograms showing staining of 
MCF7 cells with scFv-Fcs followed by Cy5-conjugated secondary antibody. Isotype control was an anti 
HPAG antibody expressed in scFv-Fc format.
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2. 7. Investigating inhibitory effect of antibodies in scFv-Fc format
We wanted to investigate if the antibodies expressed in scFv-Fc format have an inhibitory effect on 
TG2 enzymatic activity. The inhibitory effect of the antibodies was tested by in vitro transamidation 
assay in solid surface and in solution. In the assay made on solid surface antibodies were used in 
increasing concentrations ranging from 12-48nM. As negative control a non TG2 specific antibody 
anti-HPAG, while as positive control an anti TG2 antibody (hAb004) with high inhibitory effect 
was used. Inhibition was considered significant over 60%. Epitope 1. antibodies representing the 
major epitope group of anti-TG2 antibodies had no inhibitory effect on the enzyme’s activity. As, 
well as Epitope 1., Epitope group 3. and Epitope group 4. were also shown non inhibitory. Of the 
tested antibodies only Epitope 2. antibody (4.2) had considerable inhibitory effect (Figure 2.19.). 
Figure  2.19.  Inhibitory effect of antibodies in scFv-Fc format. ELISA plates coated with hTG2 and 
antibodies in scFv-Fc format. TG2 was incubated with increasing antibody concentration ( 12-48nM) . 
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Antibodies in scFv-Fc format were tested for their inhibitory effect also in solution. Also in the test 
made in solution Epitope 1. antibodies had no inhibitory effect on TG2 (data not shown) indicating 
that anti-TG2 antibodies belonging to the major epitope cluster do not inhibit the enzymes activity 
in the course of CD. The other two epitope clusters ,Epitope 3 and Epitope 4 had also no inhibitory 
effect just as in the previous experiment. The Epitope 2. antibody proved to be inhibitory also in 
solution supporting the results of the previous experiment. In the figure we can see the experiment 
done on Epitope 2. (4.2) and Epitope 4. (7.27) antibody using a TG2 inhibitory antibody (hAb004) 
as positive control (Figure 2.20).The antibodies just as the control were used at 48nM 
concentration. 
 
Figure 2.20. Antibodies were tested for their inhibitory effect on TG2 enzymatic activity in solution. C(+) 
positive control ( hAb004).  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Chapter 3. Defining the role of VH/VL pairing in antigen 
recognition 
Aim of the project  
Analyzing the autoantibody response against TG2 in CD has been in the center of attention in 
autoimmune research for many years. In the previous chapter we described the use of antibodies 
originating from phage antibody libraries of CD patients to dissect the response. In a different study 
a panel of mAbs have been generated from single plasma cells of CD patient small intestinal 
biopsies to characterize the targeting of TG2 specific antibodies [284]. Antibodies were generated in 
IgG1 format and represented the natural VH-VL coupling due to the single plasma cell origin. 
These antibodies undergone similar characterization regarding epitope clustering, fibronectin 
interaction, inhibitory effect and staining csTG2 [294]. The results of the two groups are consistent 
expect one striking difference, that none of the IgG1 antibodies were able to stain csTG2. We 
wanted to investigate the reason behind this difference. One explanation is that these antibodies are 
originating from single plasma cells representing the natural VH-VL coupling, while in phage 
display the coupling is random. The binding specificity of the antibodies might also be modified in 
scFv-Fc format compared to IgG1. In order to study the possible differences arising from 
expression in different format we decided to regenerate and characterize an Epitope 1. IgG1 
antibody 693-10-B06 [294] in our scFv and scFv-Fc formats.  
Celiac antibodies against TG2 have been reported to use a specific repertoire of VH and VL chains 
having similarities and using key residues which cannot be found in healthy individuals [286]. To 
further characterize this phenomena we kept the fix VH chain of Epitope 1. antibody 693-10-B06 
[294] and paired it with Vk chains from libraries generated from the IBL of three celiac patients.The 
libraries were selected on hTG2 and clones proved to be positive on hTG2 by ELISA were 
identified by DNA sequencing. 
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3. 1. Introduction to the results 
A. Reformat Epitope 1. antibody 693-10-B06 [294] from IgG1 into scFv format. The original 
antibody 693-10-B06 was rescued with specific oligos and cloned into phagemid vector pDAN5 in 
standard VL-VH and also in inverted VH-VL order. 
B. Constructing clones in scFV format from three minilibraries of CD patients. The VH chain 
of the constructed Epitope 1. scFv in inverted format was substituted with Vk chains originating 
from three celiac libraries in phagemid vector pDAN5. The positive output generated from the Vk 
libraries were analyzed by DNA sequencing ad by phage ELISA on hTG2 and mTG2. 
C. Cloning and expression in scFv-Fc format: Reference clones were cloned into mammalian 
expression vector pMB-SV5 and expressed in scFv-Fc format in Chinese hamster ovary (CHO) 
cells. Antibodies were tested for retaining reactivity in scFv-Fc format by performing ELISA on 
different TG2 proteins. 
D. Dissecting TG2-autoantibody interaction in the extracellular environment: The effect of 
TG2-FN interaction on antibody recognition was investigated. Competition ELISA was performed 
using FN 45kDa domain to compete antibodies for binding TG2.  
Antibodies were tested to recognize cell surface TG2 by using them for staining various TG2 
expressing cell lines. 
E. Investigating inhibitory effect of antibodies in scFv-Fc format: The inhibitory properties of 
antibodies was determined by using them in vitro transamidation assays performed in solution and 
in solid surface. 
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3. 2. Reformatting Epitope 1. IgG1 into scFv format 
The IgG1 selected for the project was 693-10-B06 belonging to Epitope 1. cluster [294] and 
consisted of VH5 chain which is the most preferentially used in CD. The VL and VH chains of the 
antibody were rescued by PCR using a set of oligonucleotides that introduced the BssHII and NheI 
sites necessary for the cloning. VH and VL amplificates were assembled with loxP511 linker by 
PCR and cloned into the phagemid vector pDAN5 [387] in two different VH-VL orders (Figure 
2.21). One of the scFvs, called scFv 1 was constructed VL-loxP511-VH order which has been 
widely used in our system. To analyze if a different order of V chains causes a difference in 
antibodies properties another construct scFv INV-1 was generated in VH-loxP511-VL order. 
Figure 2.21. The two constructs scFv 1 with VL-LinkerVH order and scFv INV-1 with VH-LinkerVH order 
expressed by pDAN5 phagemid vector in M13 filamentous phage. 
The two constructed antibodies were expressed fused to the coat protein P3 of the M13 filamentous 
phage and analyzed for retaining their specificity in scFv format by ELISA on hTG2, mTG2 and 
unrelated control protein (BSA) (Figure 2.22). Both antibodies had cross-reactivity with the murine 
protein which corresponds to the reactivity of the original Epitope 1. antibody in IgG1 format. This 
indicates  that  expression  in  the  scFv format  did  not  cause  alterations  in  the  reactivity  to  TG2 
proteins with different mammalian origin. The experiment also revealed that the different VH-VL 
order in the scFv constructs did not affect the properties of the antibodies.
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Figure 2.22. Phage ELISA made using scFv 1 and scFv INV-1 on hTG2, mTG2 and BSA.
3. 3. Constructing clones in scFv format from minilibraries of CD 
patients. 
In order to study the VL usage of celiac antibodies the VH chain of scFv INV-1 was substituted 
with VL chains of three minilibraries generated from the IBL of Celiac patients (Figure 2.23). Total 
mRNA preparation of IBL was performed and followed by cDNA synthesis using random primer 
reverse transcription and normalization. The VL chains were amplified from cDNA by PCR using a 
set of oligonucleotides that recognize human Vk genes [392]. Amplified Vk chains were cloned into 
phagemid vector pDAN5 downstream loxP511 linker. Antibodies were affinity selected on hTG2 
and after every cycle of selection the eluted phages were re-amplified for the next cycle and tested 
by ELISA against hTG2.  
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Figure 2.23. Generation of INV clones. The VH chain of scFv INV-1 was substituted with different Vk 
chains (indicated in different colours) coming from cDNA libraries of three celiac patients expressed in 
pDAN5 phagemid vector by M13 filamentous phage. 
Selection output gave 28 positive clones on hTG2. Six clones belonged to Library 1., nine clones 
belonged to Library 2. and thirteen clones belonged to Library 3. The VL usage of the positive 
clones was analyzed (Table 4.1). The VL usage of clones coming from Library 1. consisted of 
IGKV1-5*03 F, IGKV1-39*01 F, IGKV1-12*01 F chains. Library 2. clones consisted of 
IGKV1-39*01 and IGKV1-12*01 chains. Library 3. was consisting of IGKV1-39*01 and 
IGKV1-5*03 F.  
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Table 2.3. Vk family usage of anti-TG2 Abs from three libraries.Three different Vk chains: IGKV1-5*03 
F (indicated in green), IGKV1-12*01 (indicated in violet) and IGKV1-39*01 F (indicated in orange). 
The distribution of the three Vk chains points out some interesting facts (Figure 2.24). From all Vk 
chains present in the three libraries IGKV1-39*01 F was the far most used one. Not only being the 
most frequently used Vk chain, IGKV1-39*01was also the only chain which was present in all 
libraries. The results support the restricted VL usage reported in CD, with a biased usage of 
IGKV1-39*01. 
Figure 2.24. The distribution of three Vk chains in total selection output 
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A number of clones were tested for their reactivity on hTG2, mTG2 and unrelated control protein 
(BSA) by phage ELISA (Figure 2.25). It was observed that the great majority of clones has lost 
reactivity towards mTG2. This indicates that different VL chains impair different reactivity 
supporting the importance of VL chain in antigen recognition. 
Figure 2.25. Phage ELISA results of four representative clones. A. Clone retaining specificity having cross-
reactivity with mTG2. B. Clones loosing reactivity on mTG2 becoming specific on hTG2. 
In order to study the response in deep we selected four representative clones (Table 2.4). The clones 
were coming from two cDNA libraries, from Library 2. clone C12 and D3 while from Library 3. 
clone A7 and H6. All four clones shared IGKV1-39*01 F which is the most used light chain in CD 
antibody response, and also was found to be the most abundant in the positive clones of the three 
cDNA library. 
Table 2.4. Clones selected to be expressed as scFv-Fc. A. Clones harboring original VH and VL. B. Clones 
sharing original VH with Vks coming from two different libraries 
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However the CDR3 region was different for each clone allowing to more precisely dissect the effect 
of minor differences in CDR region cause in antibody properties. Beyond this selected clones had 
differences in specificity, C12 being the only one retaining mTG2 reactivity. The fact that clones 
with same type of Vk chain had altered reactivity on mTG2 indicates that different CDR3 regions 
support the recognition of different epitopes.  
3. 4. Cloning and expression in scFv-Fc format 
The two clones scFv 1 and scFv INV-1 composed of the VH and VL chains of the original IgG1 
antibody [294] and the four selected clones (C12, D3, A7, H6) representing Library 2. and Library 
3. were cloned into modified pMB-SV5 vector [393] as described in the previous chapter. After 
cloning all vectors were checked by DNA sequencing and the purified plasmidic DNAs were 
transfected into CHO cells. After 72 hours cultures supernatants were analyzed for antibody 
expression by performing ELISA on hTG2, mTG2 and unrelated control protein (BSA) (Figure 
2.26.). All clones in scFv-Fc format retained the specificity experienced in the phage expressed 
scFv format.  
Figure 2.26. ELISA experiment performed on CHO supernatants 72 hours after transfection. 
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Purification was done using Protein-A agarose and production yield ranging 1-4 mg/l of culture. 
Purified scFv-Fcs were analyzed by Comassie and Western blot under reducing conditions (Figure 
2.27). Antibodies appeared at predicted molecular weight which was around the expected 55 kDa. 
Figure 2.27. Comassie staining (A) and Western blot (B) of purified scFv-Fcs. 
The specificity of purified scFv-Fcs was further dissected on hTG2 and mTG2 and by ELISA 
(Figure 2.28.) using antibody concentrations ranging from 0.1-0.5ug/ml. All of the antibodies were 
reactive on hTG2, but only scFv-Fc 1, INV-1 and C12 had cross reactivity on mTG2 as it was seen 
in the phage expressed scFv format. This indicates that the cloning and expression in scFv-Fc 
format did not alter antibody specificity. 
Figure 2.28. Saturation binding curves for selected scFv-Fcs representing two distinct group regarding 
specificity. A. Clones cross-reactive with mTG2. B. Clones specific to hTG2. Antibodies used in increasing 
concentrations from 0,1-0,5 ug/ml. 
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3. 5. Dissecting TG2-autoantibody interaction in the extracellular 
environment 
3. 5. 1. Analyzing the effect of TG2-FN interaction on antibody binding. 
Epitope 1. antibody 693-10-B06[294] has been reported to recognize the region on TG2 molecule 
which is overlapping with the FN-binding site. In order to study if the different expression format 
and different Vk chains caused differences in TG2-antibody interaction we tested the ability of 
scFv-Fcs to react with fibronectin bound TG2 (Figure 2.29.).  
Figure 2.29. Competition ELISA between scFv-Fcs and 45kDa FN domain. TG2 was pre-incubated with 
antibodies in different concentrations from 0.05-5ug/ml. The graph indicates the decrease in signal intensity 
upon increasing antibody concentration. 
All of the scFv-Fcs had decreased reactivity in the case of TG2-FN interaction. This indicates that 
the expression in different format did not interfere with recognizing the FN-binding site on TG2 
molecule. However scFv-Fc1 and scFv-Fc INV-1 harboring the original VH and VL of Epitope 1. 
antibody [294] had a more significant decrease in reactivity for FN bound TG2 compared to the 
other clones. This support that the exchange in the VL did cause alterations in epitope specificity in 
some extent. 
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3. 5. 2. Investigate the staining properties of scFv-Fcs on csTG2 
The antibodies in scFv-Fc format were tested for staining csTG2. This experiment had a particular 
interest  since it  has  been reported that  the  original  Epitope 1.  antibody in  IgG1 format  hadn’t 
recognized TG2 expressed on the surface of  iDCs [294].  This  was contradictory to our  results 
showing that Epitope 1. antibodies (2.8, 6.17) in scFv-Fc format, originating from phage antibody 
libraries stained csTG2 on the surface of high TG2 expressing cancerous cell lines. We wanted to 
investigate  if  this  difference is  caused by the smaller  size of  scFv-Fc being able to  access  the 
binding site which is displayed on cell surfaceTG2 but is not possible for the bigger IgG1 molecule 
to reach. Another issue we came across is that the coupling of VH and VL chains in antibodies 
coming from phage antibody libraries is random while the antibodies generated from single plasma 
cells  represent  the natural  coupling.  All  scFv-Fcs were tested for  staining csTG2 on high TG2 
expressing SKOV3 cell line (Figure 2.30). As a positive control scFv-Fc 2.8, described previously 
was used. As isotype control a nonTG2 specific antibody in the same scFv-Fc format was used. 
Figure 2.30. Reactivity of scFv-Fcs with csTG2. Representative flow cytometry histograms showing 
staining of MCF7 cells with scFv-Fcs. 
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Interestingly both scFv-Fc 1 and scFv-Fc INV-1 showed a strong staining on csTG2. This indicates 
that Epitope 1. antibodies can stains csTG2 and that the different expression format improved the 
staining property of the antibodies. Two clones with the same VH but different VL, scFv-Fc C12 
and scFv-Fc A7 also had positive staining. However, the other two antibody scFv-Fc D3 and scFv-
Fc H6 were negative for staining csTG2. This correlates to what we saw with antibodies coming 
from phage antibody libraries, that different, but not all epitope clusters can recognize csTG2.
3. 6. Investigating inhibitory effect of antibodies in scFv-Fc format 
The inhibitory effect on TG2 in vitro transamidating activity was analyzed for all antibodies 
expressed in scFv-Fc format. The original Epitope 1. antibody 693-10-B06 was reported not to have 
inhibitory effect on TG2 enzymatic activity [284, 294]. These results correspond what we saw with 
our VH5 antibodies originating from phage antibody libraries. Experiments were performed as 
described before. The scFv-Fcs were used in three different concentrations of 6-12-24nM. As 
negative control a non TG2 specific antibody anti-HPAG, while as positive control an anti TG2 
antibody (hAb004) with high inhibitory effect was used (Figure 2.31.).  
Figure 2.31. In vitro transamidation assay performed on solid surface. A. Clones harboring original VH and 
VL . B. Clones with different VL chains. 
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None of the antibodies had significant inhibitory effect on TG2 enzymatic activity. The very mild 
inhibition saw in scFv-Fc1 and scFv-Fc INV-1 is similar seen in other VH5 Epitope 1. antibodies 
that are not considered inhibitory. The remaining four antibodies harboring different VL chains had 
no inhibitory effect at all.  
Antibodies in scFv-Fc format were tested for their inhibitory effect in solution. Antibodies were 
used in 24nM concentration for the experiment (Figure 2.32.). As positive control for inhibition a 
TG2 inhibitory antibody (hAb004) was used while ana negative control non TG2 specific antibody 
(anti-HPAG) was used in same concentration and scFv-Fc format.The results of the experiment 
supported what we saw in ELISA, confirming that none of the antibodies have a real inhibitory 
effect on TG2 enzymatic activity. 
Figure 2.32. In vitro inhibition assay in solution. All scFv-fcs, including controls were used in 24nM 
concentration. C(+) positive control ( hAb004).  C(-)-negative control (anti-HPAG).  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DISCUSSION 
Chapter 1. Background 
Celiac disease (CD) is a gluten-sensitive enteropathy that develops in genetically susceptible 
individuals by exposure to cereal gluten proteins. The disease characterized by symptoms like 
villous atrophy and crypt hyperplasia affects 1% of the western population [186]. It has been 
revealed that the occurrence of CD is strictly dependent on dietary exposure to gluten and similar 
cereal proteins [183]. Beyond this CD also exhibits genetic background with a very strong 
association with MHC class II molecules HLA-DQ2 and HLA-DQ8 [188, 189], with these alleles 
increasing the relative risk to the disease development 30 fold [187]. It has been revealed that CD 
patients produce antibodies specific for gluten and self antigen [257]. In 1997. TG2 was identified 
as the self antigen recognized by anti-reticulin and anti-endomysium antibodies [262]. 
TG2 is the most ubiquitous and diverse member of the transglutaminase family with a great variety 
of biological functions.TG2 has been shown to be an important player in many cellular functions as 
cell attachment and migration, wound healing, angiogenesis, apoptosis and cell and transmembrane 
signaling. As a result of diverse functions, TG2 has also been implicated in numerous pathologies 
including neurodegenerative disorders, cancer and autoimmune diseases. The main enzymatic 
function of TG2 is transamidation, where enzymatically active enzyme catalyzes Ca2+-dependent 
acyl-transfer reaction between γ-carboxamide group of a protein-bound glutamine and either the ε-
amino group of a distinct protein-bound lysine residue (covalent protein cross-linking) or primary 
amines such as polyamines and histamine. In certain conditions the amine donor substrates can be 
replaced by H2O leading to deamidation of glutamine molecules by TG2, which makes the enzyme 
one of the key players in the onset of CD [32].
The specific antibody response against TG2 in the serum has become the most sensitive and 
specific serological assay used fro the diagnosis of CD [263]. TG2 specific antibodies can be found 
as IgA deposits in the small intestine of CD patients [285]. Anti-TG2 antibodies can be isolated 
from intestinal biopsy lymphocytes [286] even in the absence of detectable anti-TG2 serum level 
[281].  
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These findings pointed out that antibody response against TG2 occurs at a local level in the small 
intestine and Ab presence in the serum is attributable to spill over into the blood compartment. TG2 
specific PCs have a strong bias in their VH and VL usage with a preference of IGHV5-51, 
IGHV3-48, IGHV4-59, IGHV1-69, IGKV1-39, IGKV1-5 [284] with a dominance of IGVH5-51 
[286]. These antibodies have been shown to recognize a part of TG2 which overlaps with the FN 
binding site on the molecule [294]. TG2 specific antibodies target at least four different epitopes 
clustered in the N-terminal of TG2 [294] where epitope clusters correlate with the VH usage. So far 
none of the TG2 specific antibodies from human origin has been shown to be able to stain csTG2. 
[294]. 
Anti-TG2 antibodies have been implied to play a role in various pathologies. It has been shown that 
anti-TG2 antibodies inhibit intestinal epithelial cell differentiation, increase the intestinal epithelial 
cell [304-306] and blood vessel permeability. Anti-TG2 antibodies have been suggested to 
contribute to the onset of gluten ataxia [311-313] leading to the neurologic pathologies occurring in 
association with CD. Anti-TG2 antibodies also have been associated with a wide range of 
reproductive disorders in women. 
The aim of this study was to dissect the autoantibody response against TG2 occurring in CD. This 
involved the generation and characterization of anti-TG2 antibodies in various format to obtain a 
more precise picture about the role they play and how they act in the disease.  
 98
Discussion
Chapter 2. Developing TG2 inhibitor antibody 
The main aim of the project is to dissect the autoantibody response in CD. One characteristic of 
anti-TG2 antibodies that need to be determined is the inhibitory effect on TG2 enzymatic activity.  
In order to fulfill this we used the sequence of an Ab coming patent that has described the 
generation of a series of TG2 inhibitory Abs (ref:WO2013/175229 A1). The sequence of the best 
inhibitor, comprising of variable heavy chain IGHV3-23*01 F and variable light chain 
IGKV1-16*01 F with code hAb004, has been used to generate our antibody in scFv-Fc format 
[393] in the pMB-SV5 vector.  
In the construct the anti-TG2 scFv is fused to the Fc domain of human IgG1, allowing to have 
activity similar to full length IgGs in most assays, and the advantages of dimerization and effector 
functions provided by the Fc domain along with the benefits of the smaller size of the molecule. 
The purified monoclonal hAb004 antibody in scFv-Fc format only found to be specific to hTG2 
correlating to what has been reported in the patent.  
In  order  to  develop an inhibition  assay first  an  ELISA measuring TG2  in  vitro  transamidating 
activity on solid surface was done, based on the coupling of 5'-(biotinamido)-pentyalamine to NN-
dimethylcasein which was catalyzed by recombinant hTG2. The inhibitory effect of hAb004 was 
investigated in different concentration ranging from 24nM-0,188nM. In the experiment hAb004 
proved to have a significant inhibitory effect on TG2 enzymatic activity in a dose dependent 
manner, reaching IC50 between 0,75-0,375nM when it was used to inhibit TG2 used in 1.5nM 
concentration. This inhibitory effect is comparable to the best TG2 inhibitors reported [170]. The 
same results were gained whet hAb004 was used to inhibit TG2 activity in solution, indicating that 
the Ab is an efficient inhibitor which can be used as a control in future experiments.  
The significant inhibitory effect of the antibody also opens a wide range of applications in research 
and therapeutic purposes. TG2 is the key player in the onset of CD by deamidating glutamine 
molecules and this way generating gluten T-cell epitopes. Since the generation of the T-cell epitopes 
highly depend on the transamidation activity of TG2, targeting and inhibiting this activity of the 
enzyme provides a promising future perspective for the treatment of the disease.  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Chapter 3. Dissecting anti TG2 antibody response 
3. 1. Characterzing and clustering Abs in scFv format 
Phage antibody libraries in this study were constructed as described in Marzari et al. [286], 
generating libraries from the IBL of seven untreated adult CD patients. After several rounds of 
selection individual colonies were analyzed on hTG2 from which 28 proved to be positive.To 
further characterize the clones positive on hTG2, the reactivity with mTG2 (sharing 84% sequence 
identity with hTG2) was assessed. From the 28 positive clones 14 showed cross-reactivity with 
mTG2 while 14 were specific to hTG2. This ratio can be explained with the great homology 
between the two proteins and correlates with former studies [286, 294] showing that the major 
portion of anti-TG2 antibodies cross-react with the murine protein. 
In order to cluster the selected antibodies into epitope groups competition experiments were 
performed with reference antibodies belonging to different VH classes with different specificity. 
From the 14 clones with mTG2 cross-reactivity 11 showed competition with the two Epitope 1., 
VH5 antibodies indicating that these clones share one major epitope as it has been described before 
[294]. Epitope 1. antibodies added up to 44% of the clones and this way dominated the antibody 
response. TG2 specific clones were clustered into 3 different epitope groups by competing them 
with reference antibodies .The results indicate that while the antibodies with mTG2 cross-reactivity 
represent a homogenous Epitope 1. cluster, antibodies specific for hTG2 recognize at least three 
different epitopes on TG2 molecule. We can conclude that antibodies target at least four distinct 
regions, based on the competition pattern for TG2 binding. However, it is likely that each cluster is 
comprised of single overlapping epitopes, with competition results indicating that some of the 
epitope regions are partly overlapping. 
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3. 2. Cloning and expression in scFv-Fc format 
Five antibodies representing the four epitope clusters were selected to be cloned and expressed in 
scFv-Fc format. Two VH5 antibodies represented the most abundant Epitope 1. cluster.  
The other three less defined epitopes were represented by a single antibody. The antibody 
representing Epitope 2. belonged to VH3, the antibody representing Epitope 3. belonged to VH1 
and the Epitope 4. antibody belonged to VH3 antibody gene family. The cloning into pMB-SV5 
mammalian expression vector was characterized by BssHII/NheI cassette where selected scFvs 
were substituted with the Fc domain of human IgG1 [394]. After purification the reactivity on TG2 
molecules with different origin was analyzed for each antibody in scFv-Fc format showing that all 
of them retained specificity. This indicates that the subcloning into scFv-Fc format did not alter the 
specificity of the antibodies, pointing out that this straightforward technology is appropriate for 
dissecting the antibody response in CD. 
3. 3. Dissecting TG2-autoantibody interaction in ECM 
3. 3. 1. Analyzing the effect of TG2-FN interaction on antibody binding.
In the extracellular environment one of TG2’s major interacting partners is fibronectin (FN) [85]. 
FN has been reported to regulate cell adhesion, migration and tumorigenesis and contribute to 
multiple physiological processes including embryonic development, angiogenesis and wound 
healing. The specific binding between TG2 and FN in the ECM involves the gelatin-binding domain 
of FN and the N-terminal β-sandwich domain of TG2. The effect of TG2-FN association on 
antibody binding has been reported by a study using monoclonal antibodies isolated from single 
plasma cells of CD patients [294], showing that the mAbs assigned to epitope 1, the VH5 epitope, 
compete with FN for binding to TG2, while other epitopes were not. In order to investigate the 
effect of TG2-FN interaction on antibody binding, the selected representative antibodies were tested 
to react with FN bound TG2. The two VH5 scFv-Fcs, representing Epitope 1. lost their reactivity 
when TG2 was associated with FN, while the other three epitope clusters were not affected. 
Although we cannot rule out that the loss of reactivity in the case of Epitope 1. antibodies is due to 
conformational changes in TG2 induced by FN binding, it suggests that this epitope overlaps with 
the fibronectin binding site on TG2 molecule.  
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The results point out a possible pathogenic role of anti-TG2 Abs in CD. Anti-TG2 antibodies might 
act as competitors of FN which could lead to antibody induced displacement of TG2 from FN in the 
ECM. This may result in increased enzymatic activity due to the release of immobilized TG2. 
Increased activity of TG2 can lead to increased gluten deamidation and this way to the T-cell 
response against deamidated gluten.  
Anti-TG2 antibodies have been implied in reproductive disorders in women with CD. Anti-TG2 
antibodies have been reported to reduce trophoblast invasiveness through apoptotic damage [320] 
and implicated to interfere in the endometrial angiogenesis [323]. As TG2 mediated interaction 
between integrins and FN contributes to cell survival and angiogenesis the displacement of TG2 
from FN meshwork by Epitope 1. anti-TG2 antibodies may lead to these pathological conditions. 
TG2 has also been linked to various functions in cancer such as promoting β integrin mediated 
ovarian cancer cell adhesion to the peritoneal matrix. TG2 has been shown to induce epithelial-to-
mesenchymal transition (EMT) [98] which is a critical step in the initiation of metastasis and that 
the FN-binding domain of TG2 is sufficient to initiate this process [99, 100]. Additionally, TG2-
mediated interaction between β integrin and FN has been reported to activate cell survival pathways 
[90] and contribute to doxorubicin resistance in breast cancer cells [101], as well as cisplatin and 
dacarbazine resistance in melanoma cells [102]. Because of this the TG2-FN interaction might serve 
as a potential target for cancer therapies. Since the binding of Epitope 1. antibodies was inhibited 
when TG2 was in FN bound form this epitope group has been implied to interfere with TG2-FN 
interaction. Because this interaction plays an important role in adhesion and migration of cancer 
cells, Epitope 1. antibodies might be a potential tool to better understand the role of TG2 in cancer 
progression and also a potential therapeutic. The effect of an Epitope 1. antibody (2.8) has been 
studied in malignant pleural mesothelioma (data not shown) where matrigel adhesion was increased 
while invasion was inhibited by the antibody. This indicates that TG2-based interventions by 
Epitope 1. antibodies may be used to disrupt malignant invasion, growth and survival.  
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3. 3. 2. Investigate the staining properties of antibodies on csTG2 
TG2 has been found to be expressed on the surface of different cell types, where it interacts with 
fibronectin, integrins of the β1 and β3 subunit [85, 90, 105]. There have been several studies aiming 
to generate and test mAbs with human origin to stain csTG2 until now with no success. Anti TG2 
antibodies isolated from single plasma cells of CD patients expressed in IgG1 format were tested 
for staining csTG2 on the surface of dendritic cells [294] and none of them showed staining on 
csTG2. It has been concluded that N-terminal epitopes are not accessible when TG2 is found on cell 
surfaces, possibly due to the association of TG2 with integrins and fibronectin or other interaction 
partners. So far only two mouse monoclonal antibodies against TG2, CUB7402 and TG100, have 
been shown to be able to stain csTG2. Since these antibodies have been generated from mouse IgG1 
by immunization with purified guinea pig liver TG2 ( sharing 76% sequence identity with hTG2) 
both of these antibodies have limitations in certain research and therapeutic applications.
We wanted to investigate if the antibody expression in scFv-Fc format and the usage of higher TG2 
expressing cell lines could improve the staining of mAbs with human origin. TG100 antibody was 
used as a control to test the staining properties of our scFv-Fc antibodies in flow cytometry using 
high TG2 expressing ovarian cancer cell lines such as SKOV3 and MCF7. All antibodies were able 
to recognize csTG2 except one representing Epitope 4. The results point several things. The fact 
that  the  Epitope  4.  antibody  showed  no  staining  serves  as  a  control  for  the  scFv-Fc  format, 
indicating that the staining is not due an unspecific binding of the Fc domain. The results also 
demonstrate that multiple but not all of the epitopes are accessible when TG2 is expressed on cell 
surface. The contradiction between our results and the previously published data [294] have raised 
questions about the cause of different staining properties. One reason might be the different size of 
antibodies since the ones described in the paper were expressed as IgG1 while ours were expressed 
in scFv-Fc format. The smaller size of the scFv-Fc molecule might allow to reach the binding site 
on TG2 not  accessible  for  the  IgG1 molecule.  Another  reason could be the different  origin  of 
antibodies since the ones described in the paper [294] were coming from single PCs representing a 
natural VL/VH coupling while our antibodies are originating from phage antibody libraries where 
the  coupling  of  VH and  VL chains  is  random.  A number  of  experiments  were  carried  out  to 
investigate this phenomenon which will be described in chapter 4.
 These  antibodies  also  raise  the  possibility  to  have antibodies  with  human origin  able  to  stain 
csTG2. This would open a whole new range of applications to understand the pathomechanism of 
CD and to find ways of therapeutic interventions.
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3. 4. Investigating inhibitory effect of antibodies in scFv-Fc format
We wanted to investigate if the antibodies expressed in scFv-Fc format have an inhibitory effect on 
TG2 enzymatic activity. Of the tested antibodies only Epitope 2. antibody (4.2) had considerable 
inhibitory effect, which has been supported by the results of the experiment carried out in solution. 
This indicates that the great majority of anti-TG2 antibodies do not exert a pathogenic role by 
inhibiting TG2 enzymatic activity in the course of CD. The data correlates with findings of a 
previous paper [284] where a similar experiment was carried out using mAbs generated from single 
plasma cells positive on TG2. 
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Chapter 4. Defining the role of VH/VL pairing in 
antigen recognition 
4. 1. Reformatting Epitope 1. [294] Ab 693-10-B06 from IgG1 into scFv format. 
In the previous chapters we described the use of antibodies originating from phage antibody 
libraries of CD patients to dissect the antibody response against TG2. In a study a panel of mAbs 
have been generated from single plasma cells of CD patients to characterize the targeted epitopes of 
TG2 specific antibodies [284]. These Antibodies were generated in IgG1 format and represented the 
natural VH-VL coupling because of their single plasma cell origin. These antibodies undergone 
similar characterization regarding epitope clustering, fibronectin interaction, inhibitory effect and 
staining csTG2 [294]. These results were consistent with our findings except a striking difference, 
that none of the mAbs of different epitope groups was able to stain csTG2 expressed by iDCs. This 
was contradictory to our data showing that antibodies of three epitope clusters in scFv-Fc format 
were able to stain csTG2. Only the Epitope 4. antibody was not able to recognize the enzyme 
expressed on cell surface. This raised the question whether the different expression format or the 
difference in the VH/VL pairing is the reason behind the contradictory findings.  
In order to investigate this phenomena,we reformatted and characterized an Epitope 1. VH5 
antibody (693-10-B06) from IgG1 format [294] into scFv and scFv-Fc formats. The VH and VL 
chains were amplified and separately assembled with loxP511 linker before cloning into the 
phagemid vector pDAN5 [387] in two different VH-VL orders. scFv 1 was constructed in VL-
loxP511-VH order which has been widely used in our system, while scFv INV-1 was generated in 
VH-loxP511-VL order to analyze the possible alterations caused by the different order of the V 
chains. The two constructs were tested for retaining specificity in scFv format by expressed fused to 
the coat protein P3 of the M13 filamentous phage. Both antibodies had cross-reactivity with the 
murine protein which corresponds to the reactivity of the original Epitope 1. antibody in IgG1 
format. These results indicate that the expression in the scFv format did not cause alterations in the 
reactivity to the two TG2 proteins with different mammalian origin. The experiment also revealed 
that the different VH-VL order in the scFv constructs did not affect the specificity of the antibodies.
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4. 2. Construction and analysis of clones in scFv format from Vk libraries of CD 
patients. 
In order to dissect the VH/VL pairing of Celiac antibodies the pairing of Vk chains to a defined 
IGHV5-51*03 F chain was analyzed. In the experiment the VH chain of scFv INV-1 was 
substituted with Vk chains coming from three minilibraries generated from the IBL of Celiac 
patients. The VL chains were amplified from cDNA using a set of oligonucleotides that recognize 
human Vk genes [392]. Amplified Vk chains were cloned into phagemid vector pDAN5 
downstream loxP511 linker. 
After the selection on hTG2 from the three minilibraries all together 28 clones proved to be 
positive. It has been shown that the Vk usage was restricted to three family: IGKV1-5*03 F, 
IGKV1-39*01 F and IGKV1-12*01 F chains. IGKV1-39*01 was the most abundant chain which 
was present in all libraries. This correlates to previous findings showing that the VH/VL usage is 
restricted in CD and that the VL chains are dominated by the Vk1 [284]. 
The specificity of the positive clones was analyzed using hTG2 and mTG2. The results were 
different from what we expected, showing that the great majority of the clones lost their reactivity 
towards mTG2. Even the clones sharing the same IGKV1-39*01chain but had different specificity 
in case of differences in the CDR3 region. These findings indicate that different Vk chains impair 
different specificity. Considering that the VH domain has been reported to be the main source of 
binding energy and specificity in antigen recognition these results are particularly interesting and 
have to be considered in future studies. However, we have to note that this is not the natural VH/VL 
coupling and the effect might be considered when using phage display technology. We wanted to 
further analyze the clones in scFv-Fc format. Four representative clones were selected for 
investigation. Clones were coming from two cDNA libraries sharing IGKV1-39*01 F, the most 
used light chain in CD antibody response.The CDR3 region was different for each clone allowing to 
more precisely dissect the effect of the differences in CDR region have in antibody characteristics. 
Selected clones also had different specificity, only one out of four showing cross reactivity with 
mTG2. 
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4. 3. Cloning and expression in scFv-Fc format 
The two clones scFv 1 and scFv INV-1 composed of the VH and VL chains of the original IgG1 
antibody [294] and four selected clones harboring IGKV1-39*01 F chain were cloned into modified 
pMB-SV5 vector [393]. After purification the specificity of scFv-Fcs was dissected on hTG2 and 
mTG2. All of the antibodies were reactive on hTG2, only scFv-Fc 1, INV-1 and C12 had cross 
reactivity on mTG2 as it was seen in the scFv format.This demonstrates that the subcloning into the 
svFv-Fc format did not alter the specificity of the antibodies. 
4. 4. Dissecting TG2-autoantibody interaction in the extracellular 
environment 
4. 4. 1. Analyzing the effect of TG2-FN interaction on antibody 
binding. 
Epitope 1. antibody 693-10-B06 [294] has been reported to recognize the region on TG2 molecule 
that is overlapping with the fibronectin binding site. We wanted to investigate if the expression in 
scFv-Fc format alters this property of the antibodies. Both scFv-Fc 1 and scFv-Fc INV-1 had the 
same amount of decrease in reactivity towards FN bound TG2 as reported for the original Epitope 
1. antibody [294], indicating that neither the expression in scFv-Fc format nor the exchange of VH/
VL order caused alteration in this property.  
The four reference clones with different Vk chains originating from the two cDNA libraries also had 
a decrease in reactivity, although less significant as scFv-Fc 1 and scFv-Fc INV-1 which had the VH 
and VL chains of the original Epitope 1. antibody. This indicates that the exchange in the Vk chain 
not only caused alterations in the specificity towards mouse TG2 but also in binding to FN binding 
site on TG2 molecule. These results provide further evidence for the change in epitope recognition 
caused by different Vk chains. 
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4. 4. 2. Investigate the staining properties of scFv-Fcs on csTG2 
This experiment had a particular interest since in the previous chapter we showed data contradictory 
to the findings of a 2013 paper [294] where epitope 1. VH5 antibodies were not able to stain csTG2. 
It has been implicated that this contradictory data might be due to the different antibody origin, 
since the antibodies originating from single plasma cells  represent the natural  VH/VL coupling 
while in the case of antibodies from phage antibody libraries this coupling is random. 
Both scFv-Fc 1 and scFv-Fc INV-1 harboring original VH/VL chains of epitope 1. antibody showed 
staining on csTG2. This result supports our findings that VH5 antibodies belonging to Epitope 1. are 
able to recognize TG2 when expressed on cell surface, if they are expressed in scFv-Fc format. 
Although we cannot completely rule out that the expression in scFv-Fc instead of IgG1 format 
causes  alterations  in  epitope  recognition,  the  cross-reactivity  with  mTG2  and  the  decreased 
reactivity towards FN associated TG2 indicates that it is not the case. It is more likely that the 
smaller size of the scFv-Fc format allows to reach TG2 even if it is not accessible to IgG1. With the 
use of scFv-Fc 1 and scFv-Fc INV 1 we have antibodies with human origin representing the natural 
VH/VL coupling that can be used for future research and therapeutic purposes.
The four reference clones harboring IGKV1-39*01 F chain with different CDR3 regions were also 
tested for staining csTG2. Two out of four had strong staining on csTG2 while the others were 
negative. Interestingly one of the antibodies able to stain csTG2 was specific to hTG2 while the 
other had cross reactivity to mTG2. This indicates that multiple, but not all epitopes are accessible 
when TG2 is expressed on cell surface, corresponding to what we have shown in the previous 
chapter.
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4. 5. Investigating inhibitory effect of antibodies in scFv-Fc format 
The inhibitory effect on TG2 in vitro transamidating activity on solid surface and in solution was 
analyzed for all antibodies expressed in scFv-Fc format. Original epitope 1. antibody 
(693-10-B06 ) has been reported not to have inhibitory effect on TG2 enzymatic activity [284, 294], 
corresponding to the results we had with our VH5 antibodies originating from phage antibody 
libraries.  
Neither scFv-Fc 1 nor scFv-Fc INV-1 had significant inhibitory effect on TG2 enzymatic activity on 
solid surface. Both antibodies had a very mild inhibition, similar to other VH5 antibodies which are 
not considered inhibitory. The results were verified when the two antibodies were analyzed for the 
inhibitory effect in solution, where they showed no inhibitory effect at all.  
The four antibodies harboring different Vk chains had no inhibitory effect at all on solid surface. 
The results were the same when the antibodies were analyzed in solution. These results show that 
even if the different Vk chains were able to cause alterations in epitope recognition, they were not 
improving the inhibitory property of the original antibody.  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CONCLUSION 
The autoantibody response in CD has been in the center of attention since TG2 has been identified 
as the antigen recognized by anti-reticulin and anti-endomysium antibodies in 1997 [262]. Great 
efforts have been made to investigate the antibody response due to the possible role anti TG2 
antibodies play in the onset of the disease, however there are still many questions to be answered. 
One way to dissect the anti-TG2 antibody response is the use of “phage display antibody libraries” 
technology. 
We were able to generate and separate antibodies in phage expressed scFv format first due to their 
specificity and second by competing them with reference antibodies. We were able cluster 
antibodies into four epitope groups with great majority of clones belonging to the VH5 cluster, 
Epitope 1. After cloning and expression in the scFv-Fc format antibodies were shown to retain their 
specificity, proving the effectiveness of the method. Epitope 1. antibodies were revealed to 
recognize a region in TG2 molecule overlapping with fibronectin binding site while other epitope 
groups recognized a different region. Three out of four epitope clusters were able to stain csTG2 
indicating that multiple but not all the epitopes are accessible when TG2 is expressed on cell 
surface. Of all epitope groups only Epitope 2. showed inhibitory effect on TG2 transamidating 
activity, indicating that the majority of the antibodies do not inhibit the enzyme. 
By reconstructing an Epitope 1. VH5 antibody (693-10-B06) from IgG1 format [294] into scFv 
format we generated two constructs with different VH/VL orders that retained specificity. The VH 
chain was substituted with Vk chains originating from three cDNA libraries originating from CD 
patients. The Vk usage was restricted IGKV1-5*03 F, IGKV1-39*01 F, IGKV1-12*01 F chains, 
IGKV1-39*01 being most abundant chain, present in all libraries and reported to be the most used 
Vk in CD. Interestingly clones with same Vk chain but altered CDR region had differences in 
reactivity towards murine TG2 indicating the role these small varieties play in antigen recognition. 
The two construct with original VH/VL and four selected clones with Vk chains coming from 
cDNA libraries were generated and characterized in scFv-Fc format. All clones were shown to 
recognize the region on TG2 which is overlapping with fibronectin binding site, although different 
Vk chains caused minor alterations in the location of the epitope. Most but not all of scFv-Fcs 
recognized csTG2, supporting the previous finding that multiple but not all epitopes are accessible 
on cell surface. Antibodies showed no inhibitory effect on TG2 enzymatic activity corresponding to 
the previous results with VH5 antibodies .  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MATERIALS AND METHODS 
Chapter 1. Abbreviations 
Ab, antibody 
AP, Alkaline Phosphatase 
BCIP, 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside  
BSA, Bovine Serum Albumine  
DMC, N,N-Dimethylcasein  
DMSO, Dimetilsulfoxide  
 DNase, deoxyribonuclease 
dNTPs, deoxynucleotides 
DTT, dithiothreitol 
HRP, HorseRadish Peroxidase 
IPTG, Isopropyl β-D-1-thiogalactopyranoside  
MW, molecular weights 
NBT, NitroBlue Tetrazolium 
NC, nitrocellulose 
O/N, over night 
PBS, phosphate buffered saline 
RT, Room Temperature 
SDS-PAGE, sodium dodecyl sulphate - polyacrylamide gel electrophoresis  
TG2, Tissue transglutaminase
TMB, Tetrametilbenzidine 
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Chapter 2. Materials  
Solutions and Buffers 
• Phosphate buffered saline (PBS)                                                                                                     
8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4, 0.24 g KH2PO4 in 1000 ml H2O, final pH 7.4.  
• Phosphate buffered saline Tween 0.1% (PBST)                                                                           
PBS added with 0.1% Tween 20  
• Milk Phosphate buffered saline (MPBS)                                                                                    
PBS added with 2% non-fat milk powder.  
• 2xTY liquid broth for bacteria 
16 g Bacto-tryptone, 10 g Bacto-yeast, 5 g NaCl, final pH 7.0. If required, ampicillin 100 µg/mL, 
chloramphenicol 34 µg /mL, streptomycin 75 µg /mL  
• 2xTY Agar plates                                                                                                                            
16 g Bacto-tryptone, 10 g Bacto-yeast, 5 g NaCl, 15 g Bacto-agar, final pH 7.0. If required, 
ampicillin 100 µg/mL, chloramphenicol 34 µg /mL, streptomycin 75 µg /mL.  
• CCMB80 for preparation of competent E.coli cells  
11,8 g CaCl2 (dihydrate), 4,0 g MnCl2 (tetrahydrate), 2,0 g MgCl2 (hexahydrate), 10mM K-
acetate (pH7), 10% Glycerol, H2O to 1L. Adjust pH to 6.4 . Filtration with 0.2 µm filter.  
• TAE buffer for DNA electrophoresis on agarose gels  
0.04 M Tris-acetate, 0.001 M EDTA.  
Bacterial strains 
The bacterial strains used in this study were:  
• Escherichia coli DH5αF’ (Gibco BRL), F’/endA1 hsd17 (rK− mK+) supE44 thi-1 recA1 gyrA 
(Nalr) relA1 _ (lacZYA-argF) U169 deoR (F80dlacD-(lacZ)M15)  
• Escherichia coli BL21-CodonPlus(DE3)-RIPL strain B F– ompT hsdS(rB– mB–) dcm+ Tetr gal 
λ(DE3) endA Hte [argU proL/Camr] [argU ileY leuW Strep/Specr]  
 112
Materials and Methods
Oligonucleotides 
All primers were purchased from Biomers. 
Table 3.1 Oligonucleotide sequences 
Chapter 3. Standard protocols 
PCR (Polymerase chain reaction)  
Thermus aquaticus DNA polymerase (Thermo Fisher Scientific) was used.  
Reaction mixture: 
• Template DNA                           0.01-1ng (plasmidic DNA) 
• Sense primer                              0.5 uM 
• Antisense primer                        0.5 uM 
• Reaction buffer 10x                    2.0 ul 
• dNTPs (Promega)                       0.25 mM 
• Taq polymerase                           0.025 unit/ul              
•  H2O                                            to 20 ul 
The following cycles were performed:  
• Denaturation step, 5’ at 94°C.  
• 31 cycles of: denaturation, 45’’ at 94°C; annealing, 45’’ at 60°C; elongation, 1’’every 1000bp at 
72°C.  
• Final elongation step: 10’’ at 72°C.  
Oligo ID                        Sequence
VLPT2                            tac cta ttg cct acg gca gcc gct gga ttg tta tta ctc
VHPT2                            tgg tga tgg tga gta cta tcc agg ccc agc agt ggg ttt g
PHYGRO-SEQ-SENSE    ctg ctt act ggc tta tcg
CH2 HUMAN ANTI           cgg tcc ccc cag gag ttc agg tgc 
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DNA electrophoresis on agarose gels                                                                                       
Agarose (Sigma) gels with a concentration of 1.5 % in TAE buffer were used to separate PCR 
products; 0.8 % agarose gels were used to separate plasmidic DNA preparations, before and after 
digestions. 1 µL of ethidium bromide (2mg/mL, Sigma) was added to 50 ml of agarose gel.100 
base-pairs plus and 1KB molecular weight markers were purchased from Fermentas. 
DNA purification                                                                                                                                 
The GeneJET PCR Purification Kit (Thermo Scientific) was used for purification of DNA from 
agarose gel and reaction mixtures, following the manufacturer instructions. 
Plasmidic DNA extraction                                                                                                              
The GeneJET Plasmid Miniprep Kit (Thermo Scientific) was used for plasmidic DNA mini-
preparations (1 to 5 ml of O/N bacterial culture), following the manufacturer instructions.  
DNA digestion with restriction endonucleases                                                                                
All restriction endonucleases (BssHII, NheI) were purchased from New England Biolabs (NEB).  
Reaction mixture:  
• DNA 
• NEB Buffer 10x 
• BSA 100x 
• Restriction endonuclease, 1 unit / µg of DNA  
• H2O to 50uL  
Incubation for 1 hour at the temperature required by the specific endonuclease.  
Ligation  
Plasmidic vector DNA and insert DNA were mixed at a 1:3/1:5 ratio (number of molecules). 
T4 ligase was purchased from New England Biolabs (NEB).  
Reaction mixture:  
•  DNA (about 50ng) 
•  T4 ligase Buffer (NEB) 10x 
• T4 ligase (NEB), 1 Unit/reaction  
•  H2O to 10ul 
Incubation O/N at 16°C.  
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Preparation of competent E.coli                                                                                                          
50 mL of E.coli culture, DH5α or BL21(DE3)RIPL strains, were grown at 37°C in 2xTY liquid 
broth to OD600 0.5. Bacteria were chilled in ice for 10’ to stop growth, centrifuged at 4°C for 10’ at 
3000 rpm and the supernatant was discarded. The bacterial pellet resuspended in 8 mL of CCMB80 
solution and put in ice for 20’. After centrifuging for 10’ at 4°C, supernatant was discarded, 
bacterial pellet resuspended in 2 mL of CCMB80 and dispensed in 80 µL aliquotes. Competent cells 
were immediately used or stocked at -80°C up to four weeks.  
Bacterial transformation 
5 µL of ligation reaction mixture or 10-50ng of plasmidic preparation were transferred into a tube 
containing 80 uL of competent cells. The mixture was incubated in ice for 20’. Heat shock was 
applied at 42°C for 1 minute and 30’’; bacteria were then chilled in ice for 1 minute, resuspended in 
1 ml of liquid broth and allowed to grow at 37°C in absence of selective antibiotic for 1 hour. 
Bacteria were then plated on antibiotic-containing agar plates and grown O/N at 30°C. 
DNA Sequencing 
PCR products were purified with GeneJET PCR Purification Kit (Thermo Scientific), 
following manufacturer instructions.  
Reaction mixture for sequencing were composed of: 
• 20-100ng of purified PCR product 
•  1 µL primer (3,2µM) 
• 1 µL Terminator Ready Reaction Mix (BigDye Terminator v 1.1 Cyle Sequencing Kit-
Applied Biosystems )  
• H2O to 10µL  
Sequencing program was performed as :  
• 1’at 96°  
• 25 cycles: 15’’ at 96°; 5’’ at 50°; 4’ at 60°  
Reactions mixes were purified with CENTRI SEP Spin Columns, following manufacturer 
instructions. 5 µL of purified sequences were loaded on sequencing plates with 10 µL of formamide, 
denaturated for 2’ at 96° and analyzed with 3100 Genetic Analyzer sequencer (ABI PRISM-
HITACHI). 
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Chapter 4. Methods 
Intestinal Biopsy Lymphocyte RNA preparation and library construction  
Total RNA was prepared from 10 ml of IBL from seven previously untreated CD adult patients. 
cDNA was synthesized by using random hexamers and SuperScript II reverse transcriptase (Life 
Technologies). Ig V regions were amplified by using specific V region primers and assembled into 
scFv as reported in [286] before cloning into pDAN5.  
Recombinant TG2 production
Recombinant  hTG2 was  expressed  in  pET-28b  vector  by  E.  coli  BL21-RIPL strain,  harboring 
kanamycin resistance, while mTG2 was expressed pTrcHis-B (Invitrogen) vector by DH5αF’ cells 
harboring ampicillin resistance. Bacteria were grown in corresponding antibiotics to 0.5 OD600, 
induced with 0.2 mM, isopropyl thio-b-D-galactoside (IPTG) and incubated at 20 °C  O/N.  The 
soluble cytoplasmic fraction was prepared by extraction of pelleted bacteria with lysozyme in lysis 
buffer followed by centrifugation. The supernatant was collected and purified fragments were 
obtained by affinity chromatography of the bacterial extract on HIS-Select® Nickel Affinity Gel 
(SIGMA).
Selection and testing of phage Abs  
Phagemid particles were rescued as described in [286] and panning was performed by adding 
phages diluted in 2% nonfat milk in PBS (MPBS) to immunotubes (Nunc, Naperville, IL) coated 
with purified h TG2, washing 20 times with PBS 0.1% Tween 20, and 20 times with PBS, followed 
by elution with 1 ml of E. coli cells at 0.5 OD600 for 30 min at 37°C and overnight growth after 
addition of ampicillin, helper phage, and kanamycin. The panning procedure was repeated up to 
three times. After selection,individual clones were screened for reactivity to hTG2 by ELISA 
performed in 96 well plate. 
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Phage ELISA  
Single clones were grown in 1 mL of 2xTY added with ampicillin 37°C to OD600 0.5 They were 
infected with a wild-type helper phage without agitation. Bacteria were then centrifuged, the 
supernatant discarded and the pellet resuspended in 1 ml of 2xTY added with ampicillin and 
kanamycin and grown O/N at 28°C. Costar ELISA strips were coated with hTG2, mTG2 or BSA as 
a control protein at 3 µg/ml. Wells were blocked with 2% MPBS at RT for 45’. Bacteria were 
centrifuged for 10’ at 7000 rpm and supernatant with phages of individual clones were added to the 
wells, followed by extensive washes. Wells were added with horseradish conjugated anti-M13 
monoclonal antibody (SIGMA) diluted 1:5000 and incubated which was followed by extensive 
washes. Immunocomplexes were revealed with the chromogenic substrate 3,3′,5,5′-
Tetramethylbenzidine (Sigma), and the plate read at OD450. 
Phage Competition ELISA 
Preparation of phages as mentioned in „Phage ELISA”. Costar ELISA strips were coated with 
hTG2, mTG2 or BSA as a control protein at 3 µg/ml. Wells were blocked with and then added with 
reference antibodies in scFv-Fc format, diluted in 1:1000 and incubated for 1h at RT. Bacteria were 
centrifuged 7000RPM and 15ul supernatant of individual clones was exchanged with 15ul of well 
solution and incubated 1.5 h at RT. After extensive wash steps wells were added with horseradish 
conjugated anti-M13 monoclonal antibody (SIGMA) diluted 1:5000 and incubated 1h at RT. 
Immunocomplexes were revealed after extensive wash steps with the chromogenic substrate 3,3′,
5,5′-Tetramethylbenzidine (SIGMA), and the plate read at OD450. 
Cloning and Expression as Recombinant scFv-Fc in CHO cells 
The cloning of scFv genes was performed by extraction from phagemid pDAN5 clones by cutting 
with BssHII and NheI (NEB) enzymes for 1h at 37 °C. Modified pMB-SV5 vector was cut with 
same enzymes. After cloning individual colonies were analyzed by fingerprinting with BstNI 
enzyme (NEB) and sequencing with 3130/3130xl Genetic Analyzer (Applied biosystems). Plasmid 
DNA has been extracted from positive clones (Thermo Scientific) and transfected into CHO cells 
with using Lipofectamine® 2000 Transfection Reagent (Invitrogen).  
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Western blotting 
SDS/PAGE was performed according to standard techniques. Purified scFv-Fcs were separated by 
SDS/PAGE and transferred onto nitrocellulose (Whatman) by semi-dry blotting using the TRANS-
BLOT SD SEMI-DRY TRANSFER CELL (BIORAD). The scFv-Fcs were revealed by anti-Human 
IgG conjugated with Alakaline Phosphatase (SIGMA). 
TG2 Inhibition assay in solid surface 
Costar ELISA strips were coated with Casein,N,N –dimethylated (SIGMA) in 15µg/ml 
concentration. A pre-incubation of the following mix(100mM Tris/HCl pH 8; 10mM DTT; 5mM 
CaCl2; 150mM NaCl; XXµg of TG2 (0,1-0,01ug) and Xxug of scFv-Fc (0,7-0,1ug) was done at 
30°C for 1h. After incubation the mix was substituted with 0,2 mM EZ-Link Pentylamine-Biotin, 
added to ELISA wells and incubated at 37°Cfor 1h. After extensive wash steps Streptavidin-HRP 
(R&D Systems) working solution was added to the wells. Incorporation was revealed with 3,3′,5,5′-
Tetramethylbenzidine and H2SO4 as substrates and read at 450nm. 
TG2 Inhibition assay in solution 
A preliminary incubation step was done with the following mix: (100mM Tris/HCl pH 8; 10mM 
DTT; 5mM CaCl2; 150mM NaCl; XXµg of TG2 (0,1-0,01ug) and Xxug of scFv-Fc  (0,7-0,1ug))  at 
30°C for 1h. After incubation the mix was substituted with 0, 2 mM EZ-Link Pentylamine-Biotin 
and DMC 30ug/ml. Corresponding amount of mix was separated by SDS/PAGE and transferred 
onto nitrocellulose (Whatman) by semi-dry blotting using the TRANS-BLOT SD SEMI-DRY 
TRANSFER CELL (BIORAD). Incubation was done with Streptavidin -Alkaline Phosphatase 
antibody and revealed by NBT/BCIP (Roche). 
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ELISA assay on Fn captured TG2 
Plates were coated with 10ug/ml of full length Fn (SIGMA) or 3ug/ml TG2 protein. Incubation step 
was followed by addition of 3ug/ml TG2 for FN coated wells and PBS1x for wells coated with 
TG2. A 1h incubation step at 37°C was followed by extensive wash with PBST 0,1%. Primary 
antibodies (0,1/0,25/0,5ug/ml) were added and incubated 1h at 37°C. After wash step anti-Human-
HRP was added as secondary antibody and incubated 1h at 37°C.  Immunocomplexes were revealed 
after extensive wash steps with the chromogenic substrate 3,3′,5,5′-Tetramethylbenzidine (Sigma), 
and the plate read at OD450. 
Surface staining and FACS analysis of TG2 expressing cells 
MCF7 cells were washed with cold Staining Buffer and centrifuge 240 rcf for 5 min at 4°C.  Cell 
pellet stained  with saturating concentration of the antibody (1-2ug), diluted in 100ul of Staining 
Buffer. Cells were incubated with antibody for 20-30 min at 4°C. After wash and centrifuge step 
(240rcf for 5 min at 4°C) supernatant was carefully aspired. Cells were stained with the secondary 
antibody  anti-Human Cy5 ( Listarfish) diluted in 100ul of Staining Buffer, and incubate for 20-30 
min at 4°C, washed and fixed. 
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